Plus Therapeutics (PSTV) 10-K 24 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Jan. 31, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	CYTORI THERAPEUTICS, INC.
Entity Central Index Key	1,095,981
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 42.3
Entity Common Stock, Shares Outstanding		21,966,424
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 12,560	$ 14,338
Accounts receivable, net of reserves of $167 and $797 in 2016 and 2015, respectively	1,242	1,052
Restricted cash	350	0
Inventories, net	3,725	4,298
Other current assets	870	1,555
Total current assets	18,747	21,243
Property and equipment, net	1,157	1,631
Restricted cash	0	350
Other assets	2,336	1,521
Intangibles, net	8,447	9,031
Goodwill	3,922	3,922
Total assets	34,609	37,698
Current liabilities:
Accounts payable and accrued expenses	5,872	6,687
Current portion of long-term obligations, net of discount	6,629	0
Joint venture purchase obligation	0	1,750
Total current liabilities	12,501	8,437
Deferred revenues	97	105
Long-term deferred rent and other	17	269
Long-term obligations, net of discount, less current portion	11,008	16,681
Total liabilities	23,623	25,492
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 13,500 shares issued; no shares outstanding in 2016 and 2015	0	0
Common stock, $0.001 par value; 75,000,000 shares authorized; 21,707,890 and 13,003,893 shares issued and outstanding in 2016 and 2015, respectively	22	13
Additional paid-in capital	388,769	368,214
Accumulated other comprehensive income	1,258	996
Accumulated deficit	(379,063)	(357,017)
Total stockholders’ equity	10,986	12,206
Total liabilities and stockholders’ equity	$ 34,609	$ 37,698

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Accounts receivable, reserves	$ 167	$ 797
Stockholders’ equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	13,500	13,500
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	21,707,890	13,003,893
Common stock, shares outstanding (in shares)	21,707,890	13,003,893

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Product revenues	$ 4,656	$ 4,838
Cost of product revenues	2,715	3,186
Gross profit	1,941	1,652
Development revenues:
Government contracts and other	6,724	6,821
Total development revenues	6,724	6,821
Operating expenses:
Research and development	16,197	19,000
Sales and marketing	3,611	2,662
General and administrative	8,563	9,765
Change in fair value of warrant liabilities	0	(7,668)
Total operating expenses	28,371	23,759
Operating loss	(19,706)	(15,286)
Other income (expense):
Loss on debt extinguishment	0	(260)
Interest income	19	9
Interest expense	(2,592)	(3,379)
Other income, net	233	172
Total other expense	(2,340)	(3,458)
Net loss	(22,046)	(18,744)
Beneficial conversion feature for convertible preferred stock	0	(661)
Net loss allocable to common stockholders	$ (22,046)	$ (19,405)
Basic and diluted net loss per share allocable to common stockholders	$ (1.28)	$ (2.07)
Basic and diluted weighted average shares used in calculating net loss per share allocable to common stockholders	17,290,933	9,386,488
Comprehensive loss:
Net loss	$ (22,046)	$ (18,744)
Other comprehensive income – foreign currency translation adjustments	262	296
Comprehensive loss	$ (21,784)	$ (18,448)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ (5,702)		$ 7	$ 331,864	$ 700	$ (338,273)
Balance (in shares) at Dec. 31, 2014		5,311	6,623,225
Share-based compensation	2,041			2,041
Issuance of common stock under stock option plan and employee stock purchase plan	27			27
Issuance of common stock under stock option plan and employee stock purchase plan (in shares)			15,437
Conversion of Series A 3.6% Convertible Preferred Stock into common stock	(2)		$ 1	(3)
Conversion of Series A 3.6% Convertible Preferred Stock into common stock (in shares)		(5,311)	680,943
Issuance of common stock under stock warrant agreement, net	22,813		$ 3	22,810
Issuance of common stock under stock warrant agreement, net (in shares)			3,123,577
Sale/Issuance of common stock	10,701		$ 2	10,699
Sale/Issuance of common stock (in shares)			2,560,711
Allocation of fair value for debt-related warrants	776			776
Foreign currency translation adjustment and accumulated other comprehensive income	296				296
Net loss	(18,744)					(18,744)
Balance at Dec. 31, 2015	$ 12,206		$ 13	368,214	996	(357,017)
Balance (in shares) at Dec. 31, 2015	13,003,893		13,003,893
Share-based compensation	$ 1,080			1,080
Issuance of common stock under employee stock purchase plan	6			6
Issuance of common stock under employee stock purchase plan (in shares)			30,744
Sale/Issuance of common stock	19,478		$ 9	19,469
Sale/Issuance of common stock (in shares)			8,673,253
Foreign currency translation adjustment and accumulated other comprehensive income	262				262
Net loss	(22,046)					(22,046)
Balance at Dec. 31, 2016	$ 10,986		$ 22	$ 388,769	$ 1,258	$ (379,063)
Balance (in shares) at Dec. 31, 2016	21,707,890		21,707,890

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (22,046)	$ (18,744)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,182	1,093
Amortization of deferred financing costs and debt discount	954	979
Joint Venture acquisition obligation accretion	24	365
Provision for doubtful accounts	0	(105)
Provision for expired inventory	172	0
Change in fair value of warrants	0	(7,668)
Share-based compensation expense	1,080	2,041
(Gain) loss on asset disposal	(127)	8
Loss on debt extinguishment	0	260
Increases (decreases) in cash caused by changes in operating assets and liabilities:
Accounts receivable	(179)	328
Inventories	471	490
Other current assets	633	(637)
Other assets	(764)	363
Accounts payable and accrued expenses	(673)	1,045
Deferred revenues	(8)	3
Long-term deferred rent	(252)	(289)
Net cash used in operating activities	(19,533)	(20,468)
Cash flows from investing activities:
Purchases of property and equipment	(67)	(611)
Expenditures for intellectual property	0	(13)
Proceeds from sale of assets	131	11
Net cash provided by (used in) investing activities	64	(613)
Cash flows from financing activities:
Principal payments on long-term obligations	0	(25,032)
Proceeds from long-term obligations	0	17,700
Debt issuance costs and loan fees	0	(1,854)
Joint Venture purchase payments	(1,774)	(1,623)
Proceeds from exercise of employee stock options and warrants	0	4,997
Proceeds from sale of common stock	21,467	29,054
Costs from sale of common stock	2,084	2,370
Dividends paid on preferred stock	0	(75)
Net cash provided by financing activities	17,609	20,797
Effect of exchange rate changes on cash and cash equivalents	82	0
Net decrease in cash and cash equivalents	(1,778)	(284)
Cash and cash equivalents at beginning of period	14,338	14,622
Cash and cash equivalents at end of period	12,560	14,338
Cash paid during period for:
Interest	1,618	1,994
Final payment fee on long-term debt	0	1,839
Supplemental schedule of non-cash investing and financing activities:
Issuance costs paid in common stock	189	0
Conversion of preferred stock into common stock	0	10
Declared dividend related to preferred stock	0	3
Fair value of warrants allocated to additional paid-in capital	$ 0	$ 776

Organization and Operations

Organization and Operations	12 Months Ended
	Dec. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Operations	1. Organization and Operations The Company Cytori Therapeutics, Inc. (NASDAQ: CYTX) develops cell therapies uniquely formulated and optimized for specific diseases and medical conditions with a primary focus on impaired hand function in scleroderma, in addition to our other pipeline areas, such as osteoarthritis of the knee, stress urinary incontinence, and full thickness thermal burns including those complicated by radiation exposure. Principles of Consolidation The accompanying consolidated financial statements include our accounts and those of our subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. We have five wholly-owned subsidiaries located in Japan, United Kingdom, Switzerland, India and Spain that have been established primarily to support our sales and marketing activities in these regions. Reverse Stock Split On May 10, 2016, following stockholder and Board approval, an amendment (the “Amendment”) to the Company’s amended and restated certificate of incorporation, as amended, was filed and declared effective, which Amendment effectuated a one-for-fifteen (1:15) reverse stock split of the Company’s (i) outstanding common stock, and (ii) common stock reserved for issuance upon exercise of outstanding warrants and options (the “1:15 Reverse Stock Split”). Upon effectiveness of the 1:15 Reverse Stock Split, the number of shares of the Company’s common stock (x) issued and outstanding decreased from approximately 200 million shares (as of May 10, 2016) to approximately 13.3 million shares; (y) reserved for issuance upon exercise of outstanding warrants and options decreased from approximately 16 million shares to approximately 1.1 million shares, and (z) reserved but unallocated under our current equity incentive plans (including the stockholder-approved share increase to the Company’s 2014 Equity Incentive Plan) decreased from approximately 6.5 million common shares to approximately 0.4 million common shares. In connection with the 1:15 Reverse Stock Split, the Company also decreased the total number of its authorized shares of common stock from 290 million to 75 million. The number of authorized shares of preferred stock remained unchanged. Following the 1:15 Reverse Stock Split, certain reclassifications have been made to the prior periods’ financial statements to conform to the current period's presentation. The Company adjusted stockholders’ equity to reflect the 1:15 Reverse Stock Split by reclassifying an amount equal to the par value of the shares eliminated by the split from common stock to the additional paid-in capital during the first quarter of fiscal 2016, resulting in no net impact to stockholders' equity on our consolidated balance sheets. The Company’s shares of common stock commenced trading on a split-adjusted basis on May 12, 2016. Proportional adjustments for the reverse stock split were made to the Company's outstanding stock options, warrants awards issued and available under and equity incentive plans for all periods presented. Certain Risks and Uncertainties Our prospects are subject to the risks and uncertainties frequently encountered by companies in the early stages of development and commercialization, especially those companies in rapidly evolving and technologically advanced industries such as the biotech/medical device field. Our future viability largely depends on our ability to complete development of new products and receive regulatory approvals for those products. No assurance can be given that our new products will be successfully developed, regulatory approvals will be granted, or acceptance of these products will be achieved. The development of medical devices for specific therapeutic applications is subject to a number of risks, including research, regulatory and marketing risks. There can be no assurance that our development stage products will overcome these hurdles and become commercially viable and/or gain commercial acceptance. Liquidity and Going Concern We incurred net losses of $22.0 million and $18.7 million for the years ended December 31, 2016 and 2015, respectively. We have an accumulated deficit of $379.1 million as of December 31, 2016. Additionally, we have used net cash of $19.5 million and $20.5 million to fund our operating activities for the years ended December 31, 2016 and 2015, respectively. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Further, our Loan and Security Agreement, or the Loan and Security Agreement, with Oxford Finance, LCC, or Oxford, as further described in Note 8, requires to maintain a minimum of $5.0 million in unrestricted cash and cash equivalents on hand to avoid an event of default under the Loan and Security Agreement. Based on our cash and cash equivalents on hand of approximately $12.6 million at December 31, 2016, and our obligation to make payments of principal of $0.6 million plus accrued interest in monthly installments, we estimate that we must raise additional capital and/or obtain a waiver or restructure the Loan and Security Agreement on or before May 2017 to avoid defaulting under our $5.0 million minimum cash/cash equivalents covenant. To date, these operating losses have been funded primarily from outside sources of invested capital including our recently completed Lincoln Park Purchase Agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) and the Rights Offering (each defined below), our at-the-market (“ATM”) equity facility, the Loan and Security Agreement and gross profits. We have had, and we will likely continue to have, an ongoing need to raise additional cash from outside sources to fund our future clinical development programs and other operations. On June 15, 2016, we closed a rights offering originally filed under Form S-1 registration statement in April 2016 (the “Rights Offering”). Pursuant to the Rights Offering, we sold an aggregate of 6,704,852 units consisting of a total of 6,704,852 shares of common stock and 3,352,306 warrants, with each warrant exercisable for one share of common stock at an exercise price of $3.06 per share, resulting in total gross proceeds to Cytori of $17.1 million. See Note 11 for further discussion on the Rights Offering. On December 22, 2016, we entered into a purchase agreement and a registration rights agreement, with Lincoln Park pursuant to which we have the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $20.0 million in amounts of shares, of the Company’s common stock, over the 30-month period commencing on the date that a registration statement, which the Company filed with the Securities and Exchange Commission (the “SEC”) on December 30, 2016. See Note 11 for further discussion on the Lincoln Park agreement. Pursuant to these securities transactions and related equity issuances, as well as anticipated gross profits and potential outside sources of capital, we believe we have sufficient cash to fund operations through Q2 2017. We continue to seek additional capital through product revenues, strategic transactions, including extension opportunities under our awarded U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (“BARDA”) contract, and from other financing alternatives. Without additional capital, current working capital and cash generated from sales will not provide adequate funding for research, sales and marketing efforts and product development activities at their current levels. If sufficient capital is not raised, we will at a minimum need to significantly reduce or curtail our research and development and other operations, and this could negatively affect our ability to achieve corporate growth goals. Should we be unable to raise additional cash from outside sources, this will have a material adverse impact on our operations. The accompanying consolidated financial statements have been prepared assuming we will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. Reclassifications Certain immaterial reclassifications have been made to certain of the prior years’ consolidated financial statements to conform to the current year presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, measuring accretion expense related to our acquisition of the joint venture, and valuing allowances for doubtful accounts and inventory reserves. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary. Cash and cash equivalents We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents includes cash in readily available checking and savings accounts. We held no investments as of December 31, 2016 and 2015. We maintain our cash at insured financial institutions. Restricted Cash Restricted cash consists of cash invested in a certificate of deposit used as collateral for the issuance of a letter of credit pursuant to a lease agreement entered into on April 2, 2010 (amended November 4, 2011) for leasing of property at 3020 and 3030 Callan Road, San Diego, California. The lease agreement required us to execute a letter of credit for $0.4 million naming the landlord as a beneficiary. It is required by the landlord that we maintain $0.4 million as restricted cash for the duration of the lease, which expires October 31, 2017. Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company periodically assesses the collectability of accounts receivable on a specific customer basis considering factors such as evaluation of collectability, historical collection experience, the age of accounts receivable and other currently available evidence of the collectability, and records an allowance for doubtful accounts for the estimated uncollectible amount. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Inventories Inventories include the cost of material, labor, and overhead related to Celution devices, consumable kits, and reagents, and are stated at the lower of cost, determined on the first-in, first-out (FIFO) method, or market. We periodically evaluate our on-hand stock and make appropriate provisions for any stock deemed excess or obsolete. Manufacturing costs resulting from lower than “normal” production levels are expensed as incurred. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from three to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred. Impairment We assess certain of our long-lived assets, such as property and equipment and intangible assets other than goodwill, for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. We recognized no impairment losses during any of the periods presented in these financial statements. Goodwill and Intangibles Goodwill is reviewed for impairment annually or more frequently if indicators of impairment exist. We perform our impairment test annually during the fourth quarter. The impairment evaluation is performed assuming the Company operates in a single operating segment and reporting unit. First the Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. If deemed necessary, a two-step test is used to identify the potential impairment and to measure the amount of goodwill impairment, if any. The first step is to compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is considered not impaired; otherwise, there is an indication that goodwill may be impaired and the amount of the loss, if any, is measured by performing step two. Under step two, the impairment loss, if any, is measured by comparing the implied fair value of the reporting unit goodwill with the carrying amount of goodwill. There was no indication of impairment of goodwill for all periods presented. Separable intangible assets that have finite useful lives are amortized over their respective useful lives. As part of the May 2013 acquisition of the Joint Venture (see Note 4), we acquired intangible assets which consisted primarily of contractual license rights that had previously enabled the Joint Venture to conduct development and manufacturing activities pertaining to certain aspects of Cytori’s Celution technology. The useful life of the identifiable intangible assets was estimated based on the assumed future economic benefit expected to be received from the assets. The technology was valued at $9.4 million and is being amortized on a straight-line basis over a useful life of eleven years, commensurate with the expected cash flows. The changes in the carrying amounts of finite-life intangible assets and goodwill for the years ended December 31, 2016 and 2015 are as follows (in thousands): December 31, 2016 Other intangibles, net: Beginning balance $ 9,031 Increase — Amortization (584 ) Ending balance 8,447 Goodwill, net: Beginning balance 3,922 Increase (decrease) — Ending balance 3,922 Total goodwill and other intangibles, net $ 12,369 December 31, 2015 Other intangibles, net: Beginning balance $ 9,415 Increase 13 Amortization (397 ) Ending balance 9,031 Goodwill, net: Beginning balance 3,922 Increase (decrease) — Ending balance 3,922 Total goodwill and other intangibles, net $ 12,953 Warrant Liability In connection with the October 2014 Securities Purchase Agreement, the Company issued common stock purchase warrants (the “October 2014 Warrants”) to certain institutional investors with certain exercise price reset features. Each warrant had an initial exercise price of $0.5771 per share, was exercisable six months and one day after the date of issuance and was to expire five years from the date on which it was initially exercisable. Pursuant to the second closing of the May 2015 Securities Purchase Agreement, the exercise price of these warrants was reset to $0.3263. The initial fair value of the liability associated with these warrants was $10.0 million and it decreased to $3.3 million as of December 17, 2015 when these warrants were cashless exercised by all holders. In May 2015, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell up to $25 million of units, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock, in a registered direct offering. The May 2015 Securities Purchase Agreement contemplated two closings, the first of which occurred on May 8, 2015, the second of which occurred upon satisfaction of certain conditions precedent, including, but not limited to, receipt of required stockholder approval, on August 27, 2015. Each warrant issued at the initial closing (the “May 2015 Warrants”) had an initial exercise price of $1.02 per share, was exercisable six months and one day after the date of issuance and expires five years from the date on which it is initially exercisable. Each warrant issued at the second closing (the “August 2015 Warrants”) had an initial exercise price of $0.401 per share, and was to expire five years from the date of issuance. The initial fair value of the liability associated with the May 2015 Warrants was $14.3 million and it decreased to $5.0 million as of December 17, 2015 when these warrants were cashless exercised by all holders. The initial fair value of the liability associated with the August 2015 Warrants was $1.6 million, and it decreased to $1.5 million as of December 17, 2015, when these warrants were cashless exercised by all holders. On December 17, 2015, the Company and the holders of October 2014 Warrants agreed to amend the October 2014 Warrants pursuant to an Amendment to Common Stock Purchase Warrant (the “2014 Amendment”). Also on December 17, 2015, the Company and the holders of the May 2015 Warrants and the August 2015 Warrants (collectively the “2015 Warrants”) agreed to amend the 2015 Warrants pursuant to an Amendment to Series A-1 Warrant to Purchase Common Stock and Amendment to Series A-2 Warrant to Purchase Common Stock, respectively (the “2015 Amendment” and, together with the 2014 Amendment, the “Warrant Amendments”). The Warrant Amendments provide that the holders may exercise their warrants on a “cashless exercise” basis in whole on or prior to December 31, 2015, whereby each exercising holder of the amended 2015 Warrants would receive 0.75 shares for each warrant share exercised and each exercising holder of the amended 2014 Warrants would receive 0.69 shares for each warrant share exercised. In addition, the Warrant Amendments removed certain provisions which provided that the exercise price of the Warrants would be reset in the event of certain equity issuances by the Company for a price below the exercise price of the Warrants as of the time of such issuance. All warrants were cashless exercised on or before December 31, 2015. The warrants were not traded in an active securities market and, as such, the estimated fair value as of their exercise date on December 17, 2015 was determined by using the Monte Carlo option pricing model. The 2014 and 2015 warrants were settled on or prior to December 31, 2015. Revenue Recognition Product Sales We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured. We evaluate customers that have not developed a sufficient payment history with us or for whom a letter of credit is not in place at the time of the transaction and defer revenues until collectability is reasonably assured. For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement. If the other revenue recognition criteria are met, revenue for these product sales is recognized upon delivery to the customer as all risks and rewards of ownership have been substantively transferred to the customer at that point. For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue. The customer’s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products. For sales where all revenue recognition criteria are not met, revenue is deferred and related inventory remains on our books. Concentration of Significant Customers & Geographical Sales For the year ended December 31, 2016, our sales were concentrated with respect to two distributors and three direct customers, which comprised 65% of our product revenue recognized. Two direct customers accounted for 57% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2016. For the year ended December 31, 2015, our sales were concentrated with respect to one distributor and four direct customers, which comprised 63% of our product revenue recognized. Two direct customers accounted for 73% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2015. Product revenues, classified by geographic location, are as follows (in thousands): Years ended December 31, 2016 2015 Product Revenues % of Total Product Revenues % of Total Americas $ 936 20 % $ 982 20 % Japan 3,279 71 % 2,394 50 % EMEA 379 8 % 675 14 % Asia Pacific 62 1 % 787 16 % Total product revenues $ 4,656 100 % $ 4,838 100 % Development Revenues We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $6.7 million and $6.8 million in BARDA revenue for the years ended December 31, 2016 and 2015, respectively. Research and Development Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of our products, regulatory fees, the purchase of laboratory supplies, and pre-clinical and clinical studies as well as salaries and benefits for our research and development employees. Also included in research and development expenditures are costs incurred to support the government reimbursement contract, including $6.3 million and $6.3 million of qualified expenses that were incurred for the years ended December 31, 2016 and 2015, related to our government contract with BARDA. Deferred Financing Costs and Other Debt-Related Costs Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December 31, 2016 and 2015, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. Share-Based Compensation We recognize the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and non-employee director is required to provide service in exchange for the award. We estimate the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term is calculated based on historical data for and applied to all employee awards as a single group as we do not expect (nor does historical data suggest) substantially different exercise or post-vesting termination behavior amongst our employee population. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term. Segment Information For the years ended December 31, 2016 and 2015, all of our financial results relate to cell therapy, therefore we report our results in one operating segment. Loss Per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented. We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the years ended December 31, 2016 and 2015, as their inclusion would be antidilutive. Potentially dilutive securities excluded from the calculations of diluted loss per share were 4.2 million as of December 31, 2016, which includes 3.6 million outstanding warrants and 0.6 million options and restricted stock awards. Potentially dilutive securities excluded from the calculations of diluted loss per share were 12.3 million as of December 31, 2015. Recent Accounting Pronouncements In May 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-12, Revenue from Contracts with Customers In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In July 2015, FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of certain cash receipts and cash payments In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Restricted Cash In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Clarifying the Definition of a Business In February 2017, the FASB recently issued ASU 2017-04, Simplifying the Test for Goodwill Impairment

Agreement with Lorem Vascular

Agreement with Lorem Vascular	12 Months Ended
	Dec. 31, 2016
Agreement With Lorem Vascular [Abstract]
Agreement With Lorem Vascular	3. Agreement with Lorem Vascular On October 29, 2013, we entered into an agreement with Lorem Vascular to commercialize Cytori Cell Therapy (OICH-D3) for the cardiovascular, renal and diabetes markets, in China, Hong Kong, Malaysia, Singapore and Australia (License/Supply Agreement), and a Common Stock Purchase Agreement. On January 30, 2014, we entered into the Amended and Restated License/Supply Agreement with Lorem Vascular (the “Restated Agreement”) which restated the License/Supply Agreement in its entirety and expanded the licensed field to all uses excepting alopecia (hair loss). Under the Restated Agreement, Lorem Vascular committed to pay up to $500 million in license fees in the form of revenue milestones. In addition, Lorem Vascular is required to pay us 30% of their gross profits in China, Hong Kong and Malaysia for the term of the agreement. In addition, Lorem Vascular has agreed to purchase the Cytori Celution® System and consumables under the Restated Agreement. Pursuant to the related Common Stock Purchase Agreement, Cytori sold Lorem Vascular 8.0 million shares of Cytori common stock at $3.00 per share for a total of $24.0 million. The equity purchased was closed in two equal installments, in November 2013 and January 2014. Lorem Vascular initially purchased approximately $1.8 million in Celution® devices and consumables in December 2013. In addition to this purchase, upon achieving regulatory clearance from the Chinese Food and Drug Administration (“CFDA”), Cytori’s license agreement with Lorem Vascular obligates Lorem Vascular to purchase an opening order of 23 Celution Systems and 1,100 Celution Consumable Sets. Class I regulatory clearance was granted in April 2015. There were no business transactions with Lorem Vascular during the year ended December 31, 2016. As of December 31, 2015, Lorem Vascular has partially satisfied this purchase order.

Transactions with Olympus Corpo

Transactions with Olympus Corporation	12 Months Ended
	Dec. 31, 2016
Joint Venture Termination Agreement [Abstract]
Transactions with Olympus Corporation	4. Transactions with Olympus Corporation Under our Joint Venture Termination Agreement (“Termination Agreement”), dated May 8, 2013, with Olympus Corporation (“Olympus”), we were required to pay Olympus a total purchase price of $6.0 million within two years of the date of the Termination Agreement. Pursuant to amendments to the Termination Agreement, dated April 30, 2015 and January 8, 2016, the Company’s repayment obligations were extended through May 8, 2016. We made payments under the Termination Agreement totaling approximately $4.2 million through December 31, 2015, as well as separate payments of $0.5 million each in January 2016 and April 2016, and paid the remaining balance of $0.8 million before the May 8, 2016 due date. There were no outstanding obligations to Olympus as of December 31, 2016.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2016
Financial Instruments Financial Liabilities Balance Sheet Groupings [Abstract]
Fair Value	5. Fair Value Measurements Fair value measurements are market-based measurements, not entity-specific measurements. Therefore, fair value measurements are determined based on the assumptions that market participants would use in pricing the asset or liability. We follow a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below: • Level 1: Quoted prices in active markets for identical assets or liabilities. • Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. • Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable in active markets. As of December 31, 2016 and 2015, we did not have any assets or liabilities measured at fair value presented on our balance sheets. The 2014 and 2015 warrants included exercise price reset features (down-round protection) and were accounted for as liabilities, with changes in the fair value included in net loss for the respective periods. Because some of the inputs to our valuation model were either not observable or were not derived principally from or corroborated by observable market data by correlation or other means, the warrant liability was classified as Level 3 in the fair value hierarchy. All of these warrants were cashless exercised on or before December 31, 2015. The following table summarizes the final valuation pertaining to the warrants that were previously included in our Level 3 warrant liabilities (in thousands): Warrant liability December 31, 2015 Balance as of December 31, 2014 $ 9,793 Additions to warrant liability 15,979 Exercised warrants (18,104 ) Change in fair value (7,668 ) Balance as of December 31, 2015 $ — Financial Instruments We disclose fair value information about all financial instruments, whether or not recognized in the balance sheets, for which it is practicable to estimate fair value. The disclosures of estimated fair value of financial instruments at December 31, 2016 and 2015, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair value amounts. The carrying amounts for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to the short-term nature of these instruments. If quoted market prices are not available, we calculate the fair value of our fixed rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to the debt. At December 31, 2016 and 2015, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows (in thousands): December 31, 2016 December 31, 2015 Fair Value Carrying Value Fair Value Carrying Value Debt $ 17,611 $ 17,637 $ 16,844 $ 16,681 Carrying value is net of debt discount of $1.2 million and $2.1 million as of December 31, 2016 and 2015, respectively. The fair value of debt is classified as Level 3 in the fair value hierarchy as some of the inputs, primarily the effective interest rate, to our valuation model are either not observable quoted prices or are not derived principally from or corroborated by observable market data by correlation or other means. Nonfinancial Assets and Liabilities We apply fair value techniques on a non-recurring basis associated with: (1) valuing potential impairment losses related to goodwill which are accounted for pursuant to the authoritative guidance for intangibles—goodwill and other; and (2) valuing potential impairment losses related to long-lived assets which are accounted for pursuant to the authoritative guidance for property, plant and equipment.

Composition of Certain Financia

Composition of Certain Financial Statement Captions	12 Months Ended
	Dec. 31, 2016
Composition Of Certain Financial Statement Captions [Abstract]
Composition of Certain Financial Statement Captions	6. Composition of Certain Financial Statement Captions Inventories, net As of December 31, 2016 and 2015, inventories, net, were comprised of the following (in thousands): December 31, 2016 2015 Raw materials $ 885 $ 1,009 Work in process 1,021 816 Finished goods 1,819 2,473 $ 3,725 $ 4,298 Other Current Assets As of December 31, 2016 and 2015, other current assets were comprised of the following (in thousands): December 31, 2016 2015 Prepaid supplies, current $ 734 $ 995 Prepaid insurance 83 300 Other receivables 53 260 $ 870 $ 1,555 Property and Equipment, net As of December 31, 2016 and 2015, property and equipment, net, were comprised of the following (in thousands): December 31, 2016 2015 Manufacturing and development equipment $ 4,256 $ 5,464 Office and computer equipment 1,953 1,939 Leasehold improvements 3,399 3,391 9,608 10,794 Less accumulated depreciation (8,451 ) (9,163 ) $ 1,157 $ 1,631 Depreciation expense totaled $0.7 million and $0.7 million for the years ended December 31, 2016 and 2015, respectively. Other Assets As of December 31, 2016 and 2015, other assets were comprised of the following (in thousands): December 31, 2016 2015 Prepaid supplies, long-term $ 1,838 $ 996 Deposits 498 525 $ 2,336 $ 1,521 Accounts Payable and Accrued Expenses As of December 31, 2016 and 2015, accounts payable and accrued expenses were comprised of the following (in thousands): December 31, 2016 2015 Accrued expenses $ 1,752 $ 2,022 Accounts payable 1,332 1,009 Accrued payroll and bonus 989 1,058 Accrued legal fees 614 372 Accrued vacation 502 573 Accrued R&D studies 347 1,117 Deferred rent 215 221 Accrued accounting fees 121 315 $ 5,872 $ 6,687

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of December 31, 2016, we have clinical research study obligations of $3.3 million, $3.2 million of which are expected to be complete within a year. Should the timing of the clinical trials change, the timing of the payment of these obligations would also change. We lease facilities for our headquarters office location as well as international office locations. As of December 31, 2016, we have remaining lease obligations of $1.8 million, all of which is expected to be completed within a year. Rent expense, which includes common area maintenance, for the years ended December 31, 2016 and 2015 was $2.5 million and $2.5 million, respectively. We are party to an agreement with Roche Diagnostics Corporation, our sole supplier of reagents, which requires us to make certain product purchase minimums. Pursuant to the agreement, as of December 31, 2016, we have a minimum purchase obligation as follows: Years Ending December 31, Obligation 2017 $ 1,074 2018 1,074 2019 1,473 2020 1,473 2021 1,473 Total $ 6,567 We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. Management believes that any liability to us that may arise as a result of currently pending legal proceedings will not have a material adverse effect on our financial condition, liquidity, or results of operations as a whole.

Long-term Obligations

Long-term Obligations	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-term Obligations	8. Long-term Obligations On September 29, 2014 we entered into a 2nd Amendment to the 2013 Loan and Security Agreement (the “2013 Loan Agreement”) with Oxford and Silicon Valley Bank. Pursuant to the amended 2013 Loan Agreement, and we were provided a conditional waiver of principal payments subject to meeting certain capital raise requirements, which we achieved in October. The waiver of principal payments continued through April 1, 2015 and we were then required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term Loan through the maturity date. On May 29, 2015, we entered into the Loan and Security Agreement, dated May 29, 2015 (the “Loan and Security Agreement”), with Oxford, pursuant to which Oxford funded an aggregate principal amount of $17.7 million (“Term Loan”), subject to the terms and conditions set forth in the Loan and Security Agreement. The Term Loan accrues interest at a floating rate of at least 8.95% per annum, comprised of three-month LIBOR rate with a floor of 1.00% plus 7.95%. Pursuant to the Loan and Security Agreement, we were previously required to make interest only payments through June 1, 2016 and thereafter we were required to make payments of principal and accrued interest in equal monthly installments sufficient to amortize the Term loan through June 1, 2019, the maturity date. On February 23, 2016, we received an acknowledgement and agreement from Oxford related to the positive data on our U.S. ACT-OA clinical trial. As a result, pursuant to the Loan and Security Agreement, the period for which we are required to make interest-only payments was extended from July 1, 2016 to January 1, 2017. All unpaid principal and interest with respect to the Term Loan is due and payable in full on June 1, 2019. At maturity of the Term Loan, or earlier repayment in full following voluntary prepayment or upon acceleration, we are required to make a final payment in an aggregate amount equal to approximately $1.1 million. In connection with the Term Loan, on May 29, 2015, we issued to Oxford warrants to purchase an aggregate of 94,441 shares of our common stock at an exercise price of $10.35 per share. These warrants became exercisable as of November 30, 2015 and will expire on May 29, 2025 and, following the authoritative accounting guidance, are equity classified. In connection with the Loan and Security Agreement, we prepaid all outstanding amounts under our prior loan agreement with Oxford and Silicon Valley Bank, at which time the Company’s obligations under the prior loan agreement immediately terminated. We paid approximately $25.4 million to Oxford and Silicon Valley Bank, consisting of the then outstanding principal balance due of approximately $23.4 million, accrued but unpaid interest of approximately $0.2 million, final payment and other agency fees of approximately $1.8 million and other customary lender fees and expenses. For Oxford, we accounted for this Term Loan as a debt modification. We retired $3.1 million of the principal of the previous loan and the corresponding unamortized fees were expensed. The remaining fees of $0.8 million were recorded as debt discount, and along with the new loan fees, are amortized as an adjustment of interest expense using the effective interest method. For Silicon Valley Bank, which did not participate in the Term Loan, the payoff of the loan was accounted for as debt extinguishment. Accordingly, a total loss on debt extinguishment of $0.3 million was recorded in 2015, which includes the unamortized fees and discounts along with final payment fees. We allocated the aggregate proceeds of the Term Loan between the warrants and the debt obligations based on their relative fair values. The fair value of the warrants issued to Oxford was calculated utilizing the Black-Scholes option pricing model. The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, expected term and risk-free interest rates. The expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free interest rate for period within the contractual life of the warrant is based on the U.S. Treasury yield in effect at the time of grant. We amortize the relative fair value of the warrants at the issuance date as a discount of $0.8 million over the term of the loan using the effective interest method, with an effective interest rate of 14.95%. The Term Loan is collateralized by a security interest in substantially all of the Company’s existing and subsequently acquired assets, subject to certain exceptions set forth in the Loan and Security Agreement and excluding its intellectual property assets, which are subject to a negative pledge. The minimum liquidity covenant is $5 million. As of December 31, 2016 we were in compliance with the debt covenants. Additional details relating to the outstanding Term Loan as of December 31, 2016 and 2015 are presented in the following table (in thousands): Year ended December 31, 2016 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment* Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 136 48 Months $ 17,700 Year ended December 31, 2015 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment*** Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 136 48 Months $ 17,700 * ** As of December 31, 2016, the future contractual principal and final fee payments on all of our debt and capital lease obligations are as follows (as thousands): Years Ending December 31, 2017 $ 7,080 2018 7,080 2019 4,629 Total $ 18,789 Reconciliation of Face Value to Book Value as of December 31, 2016 Total debt and lease obligations, including final payment fee (Face Value) $ 18,789 Less: Debt discount (1,152 ) Total obligation $ 17,637 Our interest expense for the years ended December 31, 2016 and 2015 was $2.6 million and $3.4 million, respectively. Interest expense is calculated using the effective interest method, therefore it is inclusive of non-cash amortization in the amount of $1.0 million and $1.0 million, respectively, related to the amortization of the debt discount related to the capitalized loan costs and accretion of final payment.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes Due to our net losses for the years ended December 31, 2016 and 2015, and since we have recorded a full valuation allowance against deferred tax assets, there was no provision or benefit for income taxes recorded. We recorded an immaterial amount pertaining to current foreign income tax provision expense for the year ended December 31, 2016 and no components of current or deferred federal or state income tax provisions for the years ended December 31, 2015. A reconciliation of the total income tax provision tax rate to the statutory federal income tax rate of 34% for the years ended December 31, 2016 and 2015 is as follows: 2016 2015 Income tax expense (benefit) at federal statutory rate (34.00 )% (34.00 )% Income tax expense (benefit) at state statutory rate (3.41 )% (4.40 )% Mark to market permanent adjustment 0.00 % (13.91 )% Change in valuation allowance 16.75 % (7.45 )% Change in state rate (0.06 )% (0.09 )% Permanent interest adjustments 0.16 % 6.25 % Stock compensation 12.67 % 20.43 % Transfer pricing 0.00 % 18.49 % Research credit (1.44 )% (2.37 )% Foreign rate differential 0.79 % 0.69 % NOLs expiring and adjustments to NOL 6.00 % 13.92 % Other, net 2.54 % 2.44 % 0.00 % 0.00 % The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December 31, 2016 and 2015 are as follows (in thousands): 2016 2015 Deferred tax assets: Allowances and reserves $ 573 $ 673 Accrued expenses 701 951 Deferred revenue and gain-on-sale 33 39 Stock based compensation 1,947 4,547 Net operating loss carryforwards 125,182 119,000 Income tax credit carryforwards 7,764 7,437 Property and equipment, principally due to differences in depreciation 675 683 Other, net 15 16 136,890 133,346 Valuation allowance (134,873 ) (131,187 ) Total deferred tax assets, net of allowance 2,017 2,159 Deferred tax liabilities: Intangibles assets (2,017 ) (2,159 ) Total deferred tax liability (2,017 ) (2,159 ) Net deferred tax assets (liability) $ — $ — We have established a valuation allowance against our net deferred tax assets due to the uncertainty surrounding the realization of such assets. We periodically evaluate the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. We have recorded a full valuation allowance of $134.9 million as of December 31, 2016 as we do not believe it is more likely than not our net deferred tax assets will be realized. We increased our valuation allowance by approximately $3.7 million during the year ended December 31, 2016. At December 31, 2016, we had federal, and state tax loss carry forwards of approximately $344.2 million, and $158.1 million. The federal and state net operating loss carry forwards begin to expire in 2019 and 2017, respectively, if unused. At December 31, 2016, we had federal and state tax credit carry forwards of approximately $4.9 million and $4.4 million, respectively, after reduction for uncertain tax positions. The Company has not performed a formal research and development credit study with respect to these credits. The federal credits will begin to expire in 2018, if unused, and the state credits carry forward indefinitely. Pursuant to the Internal Revenue Code (“IRC”) of 1986, as amended, specifically IRC §382 and IRC §383, our ability to use net operating loss and R&D tax credit carry forwards (“tax attribute carry forwards”) to offset future taxable income is limited if we experience a cumulative change in ownership of more than 50% within a three-year testing period. We have not completed an ownership change analysis pursuant to IRC Section 382 for taxable years ended after December 31, 2007. If ownership changes within the meaning of IRC Section 382 are identified as having occurred subsequent to 2007, the amount of remaining tax attribute carry forwards available to offset future taxable income and income tax expense in future years may be significantly restricted or eliminated. Further, our deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC §382. We recognize tax benefits associated with the exercise of stock options directly to stockholders’ equity only when realized. Accordingly, deferred tax assets are not recognized for net operating loss carry forwards resulting from windfall tax benefits. At December 31, 2016, deferred tax assets do not include $1.3 million of excess tax benefits from stock-based compensation. The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company has not recognized any liability for uncertain tax positions as of December 31, 2016 and 2015. Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December 31, 2016 and 2015 (in thousands): 2016 2015 Unrecognized Tax Benefits – Beginning $ 1,987 $ 1,852 Gross increases – tax positions in prior period 1 — Gross decreases – tax positions in prior period (13 ) — Gross increase – current-period tax positions 87 135 Unrecognized Tax Benefits – Ending $ 2,062 $ 1,987 The unrecognized tax benefit amounts are reflected in the determination of the Company’s deferred tax assets. If recognized, none of these amounts would affect the Company’s effective tax rate, since it would be offset by an equal reduction in the deferred tax asset valuation allowance. The Company does not foresee material changes to its liability for uncertain tax benefits within the next twelve months. The Company’s material tax jurisdictions are United States and California. The Company is currently not under examination by the Internal Revenue Service or any other taxing authority. The Company’s tax years for 1998 (federal) and 1997 (CA) and forward can be subject to examination by the United States and California tax authorities due to the carry forward of net operating losses and research development credits.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2016
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	10. Employee Benefit Plan We implemented a 401(k) retirement savings and profit sharing plan (the “Plan”) effective January 1, 1999. We may make discretionary annual contributions to the Plan, which is allocated to the profit sharing accounts based on the number of years of employee service and compensation. At the sole discretion of the Board of Directors, we may also match the participants’ contributions to the Plan. We made no discretionary or matching contributions to the Plan in 2016 or 2015.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Stockholders Equity Note [Abstract]
Stockholders' Equity	11. Stockholders’ Equity Preferred Stock We have authorized 5 million shares of $0.001 par value preferred stock. Our Board of Directors is authorized to designate the terms and conditions of any preferred stock we issue without further action by the common stockholders. There were 13,500 shares of Series A 3.6% Convertible Preferred Stock that had been issued at December 31, 2016 and 2015, none of which were outstanding as of either date. All outstanding shares of the Series A 3.6% Convertible Preferred Stock were converted into common stock during the fourth quarter of 2014 and the first quarter of 2015 at the option of the holders. The fair value of the common stock into which the Series A 3.6% Convertible Preferred Stock was convertible on the date of issuance exceeded the proceeds allocated to the preferred stock, resulting in the beneficial conversion feature that we recognized as a dividend to the preferred stockholders and, accordingly, an adjustment to net loss to arrive at net loss allocable to common stockholders. Certain shares of Series A 3.6% Convertible Preferred Stock were not convertible until stockholder approval, which occurred in January 2015. As a result, a dividend for the beneficial conversion feature of $0.7 million was recorded during the quarter ended March 31, 2015. In connection with the 3.6% Convertible Preferred Stock outstanding at December 31, 2014, we declared a cash dividend of $0.07 million. The cash dividend was paid in January and April 2015. Common Stock In May 2015, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell up to $25.0 million of units, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock, in a registered direct offering. The purchase and sale of the units took place in two separate closings. At the initial closing, which took place on May 8, 2015, the Company received approximately $17.4 million in net proceeds from the sale of units. The second closing occurred on August 27, 2015 upon satisfaction of certain conditions, including, without limitation, stockholder vote, and the Company received approximately $2.1 million in net proceeds from the sale of 500,000 units of the 1,000,000 units available for sale at the second closing. On December 17, 2015, the Company and the holders of October 2014 warrants agreed to amend the October 2014 Warrants pursuant to an Amendment to Common Stock Purchase Warrant (the “2014 Amendment”). Also on December 17, 2015, the Company and the holders of the May 2015 Warrants and the August 2015 Warrants (collectively the “2015 Warrants”) agreed to amend the 2015 Warrants pursuant to an Amendment to Series A-1 Warrant to Purchase Common Stock and Amendment to Series A-2 Warrant to Purchase Common Stock, respectively (the “2015 Amendment” and, together with the 2014 Amendment, the “Warrant Amendments”). The Warrant Amendments provided that the holders may exercise their warrants on a “cashless exercise” basis in whole on or prior to December 31, 2015, whereby each exercising holder of the amended 2015 Warrants would receive 0.75 shares for each warrant share exercised and each exercising holder of the amended 2014 Warrants would receive 0.69 shares for each warrant share exercised. In addition, the Warrant Amendments removed certain provisions which provided that the exercise price of the Warrants would be reset in the event of certain equity issuances by the Company for a price below the exercise price of the Warrants at the time of such issuance. All 2014 Warrants and all 2015 Warrants were cashless exercised on or before December 31, 2015. During 2016, we sold 1,840,982 shares of our common stock under an at-the-market offering program (“ATM”), receiving total net proceeds of approximately $4.4 million. During 2015, we sold 5,800,000 shares of our common stock under the ATM program, receiving total net proceeds of approximately $7.2 million. Pursuant to a registration statement on Form S-1, originally filed on April 6, 2016, as amended, and declared effective by the SEC on May 26, 2016, and related prospectus (as supplemented), the Company registered, offered and sold to its participating stockholders of record as of the announced May 20, 2016 record date, one non-transferable subscription right for each share of common stock held by each stockholder as of the record date. Each right entitled the holder thereof to purchase one unit at the subscription price of $2.55 per unit, composed of one share of common stock and 0.5 of a warrant, with each whole warrant exercisable to purchase one share of common stock at an exercise price of $3.06 per share for 30 months from the date of issuance. Pursuant to the Rights Offering, which closed on June 15, 2016, the Company sold an aggregate of 6,704,852 units, resulting in total net proceeds to the Company of $15.3 million, respectively. The warrants issued pursuant to the Rights Offering are currently listed on NASDAQ under the symbol “CTYXW.” Based on the relevant authoritative accounting guidance, the warrants were equity classified at the issuance date. Upon notice to the warrant holders, the warrants may be redeemed by the Company at $0.01 per warrant prior to their expiration and exercise if the Company’s common stock closes above $7.65 per share for 10 consecutive trading days. On December 22, 2016, we entered into the Lincoln Park Purchase Agreement pursuant to which we have the right to sell to Lincoln Park and Lincoln Park is obligated to purchase up to $20.0 million in amounts of shares, of our common stock, over the 30-month period commencing on the date that a registration statement, which we filed with the SEC in December 2016. We may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 100,000 shares of common stock on any business day but in no event will the amount of a single Regular Purchase (as defined in the Lincoln Park Purchase Agreement) exceed $1.0 million. The purchase price of shares of common stock related to the Regular Purchases will be based on the prevailing market prices of such shares at the time of sales. Our sales of shares of common stock to Lincoln Park under the Lincoln Park Purchase Agreement are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 9.99% of the then outstanding shares of the common stock. There are no trading volume requirements or restrictions under the Lincoln Park Purchase Agreement. There is no upper limit on the price per share that Lincoln Park must pay for common stock under a Regular Purchase or an accelerated purchase and in no event will shares be sold to Lincoln Park on a day our closing price is less than the floor price of $0.50 per share as set forth in the Purchase Agreement. On December 22, 2016, we issued to Lincoln Park 127,419 shares of common stock with a market value on the date of issuance of approximately $0.2 million as commitment shares in consideration for entering into the Lincoln Park Purchase Agreement. We will issue up to an additional 382,258 shares of common stock on a pro rata basis to Lincoln Park only as and when shares are sold under the Lincoln Park Purchase Agreement to Lincoln Park. To date, we have sold no shares under the Lincoln Park Purchase Agreement with Lincoln Park.

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	12. Stock-based Compensation In August 2014, we adopted the 2014 Equity Incentive Plan (the “2014 Plan”), which provides our employees, directors and consultants the opportunity to purchase our common stock in the form of options (incentive or non-qualified), stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units, cash-based awards other stock-based awards, and deferred compensation awards. The 2014 Plan initially provides for issuance of 265,000 shares of our common stock. In May 2016, the Company amended the 2014 Plan to add 333,333 shares to its share pool. In August 2015, the Company amended the 2014 Plan to add 301,800 shares to its share pool. In addition, the amendment increased the number of “incentive stock options” which may be issued under the 2014 Plan by an identical amount. On December 29, 2015, we adopted the 2015 New Employee Incentive Plan (the “2015 Plan”). Awards under the 2015 Plan may only be made to an employee who has not previously been an employee or member of the Board of any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. The 2015 Plan provides for issuance of 66,666 shares. As of December 31, 2016, there are 525,965 shares of common stock remaining and available for future issuances under the 2014 Plan, which is exclusive of securities to be issued upon an exercise of outstanding options, warrants, and rights. Stock Options Generally, options issued under the 2014 Plan, are subject to four-year vesting, and have a contractual term of 10 years. Most options contain one of the following two vesting provisions: • 12/48 of a granted award will vest after one year of service, while an additional 1/48 of the award will vest at the end of each month thereafter for 36 months, or • 1/48 of the award will vest at the end of each month over a four-year period. A summary of activity for the year ended December 31, 2016 is as follows: Options Weighted Average Exercise Price Balance as of January 1, 2016 573,727 $ 44.85 Granted 347,407 $ 2.73 Expired (23,979 ) $ 104.11 Cancelled/forfeited (261,043 ) $ 32.07 Balance as of December 31, 2016 636,112 $ 24.39 Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance as of December 31, 2016 636,112 $ 24.39 7.38 $ — Vested and expected to vest at December 31, 2016 598,135 $ 25.72 7.27 $ — Exercisable at December 31, 2016 286,358 $ 47.76 5.54 $ — There were no stock options exercised in 2016 or 2015. The fair value of each option awarded during the year ended December 31, 2016 and 2015 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: Years ended December 31, 2016 2015 Expected term 6.0 years 6.0 years Risk-free interest rate 1.75 % 1.58 % Volatility 77.56 % 75.07 % Dividends — — Resulting weighted average grant date fair value $ 1.84 $ 4.50 The weighted average risk-free interest rate represents the interest rate for treasury constant maturity instruments published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, we use the weighted average of the two Federal Reserve securities closest to the expected term of the employee option. The dividend yield has been assumed to be zero as we (a) have never declared or paid any dividends and (b) do not currently anticipate paying any cash dividends on our outstanding shares of common stock in the foreseeable future. Restricted Stock Awards Generally, restricted stock awards issued under the 2014 Plan are subject to a vesting period that coincides with the fulfillment of service requirements for each award and have a contractual term of 10 years. These awards are amortized to compensation expense over the estimated vesting period based upon the fair value of our common stock on the award date. A summary of activity for the year ended December 31, 2016 is as follows: Restricted Stock Awards Weighted Average Grant Date Fair Value Balance as of January 1, 2016 31,196 $ 12.15 Vested/Released (11,568 ) $ 15.18 Cancelled/forfeited (19,113 ) $ 10.03 Balance as of December 31, 2016 515 $ 64.52 The following summarizes the total compensation cost recognized for the stock options and restricted stock awards in the accompanying financial statements (in thousands): Years ended December 31, 2016 2015 Total compensation cost for share-based payment arrangements recognized in the statement of operations (net of tax of $0) $ 1,080 $ 2,041 As of December 31, 2016, the total compensation cost related to non-vested stock options and stock awards not yet recognized for all our plans is approximately $1.0 million, which is expected to be recognized as a result of vesting under service conditions over a weighted average period of 1.58 years. To settle stock options and restricted stock awards, we will issue new shares of our common stock. At December 31, 2016, we have an aggregate of 49,708,768 shares authorized and available to satisfy option exercises under our plans.

Quarterly Information (unaudite

Quarterly Information (unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Information (unaudited)	13. Quarterly Information (unaudited) The following unaudited quarterly financial information includes, in management’s opinion, all the normal and recurring adjustments necessary to fairly state the results of operations and related information for the periods presented (in thousands): For the three months ended March 31, 2016 June 30, 2016 September 30, 2016 December 31, 2016 Product revenues $ 1,333 $ 1,126 $ 731 $ 1,466 Gross profit 766 541 113 521 Development revenues 1,585 1,699 1,879 1,561 Operating expenses (7,448 ) (8,464 ) (6,789 ) (5,670 ) Other expense, net (242 ) (181 ) (587 ) (1,330 ) Net income (loss) $ (5,339 ) $ (6,405 ) $ (5,384 ) $ (4,918 ) Beneficial conversion feature for convertible preferred stock — — — — Net income (loss) allocable to common stock holders (5,339 ) (6,405 ) (5,384 ) (4,918 ) Basic and diluted net loss per share $ (0.41 ) $ (0.43 ) $ (0.26 ) $ (0.24 ) For the three months ended March 31, 2015 June 30, 2015 September 30, 2015 December 31, 2015 Product revenues $ 902 $ 1,614 $ 766 $ 1,556 Gross profit 305 318 264 765 Development revenues 1,444 1,847 1,710 1,820 Operating expenses (22,745 ) 3,626 16 (4,656 ) Other expense, net (961 ) (1,342 ) (470 ) (685 ) Net income (loss) $ (21,957 ) $ 4,449 $ 1,520 $ (2,756 ) Beneficial conversion feature for convertible preferred stock (661 ) — — — Net income (loss) allocable to common stock holders (22,618 ) 4,449 1,520 (2,756 ) Basic and diluted net loss per share $ (3.19 ) $ 0.45 $ 0.15 $ (0.25 )

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Azaya Therapeutics, Inc. Assets On February 15, 2017 (the “Closing Date”), Cytori completed the acquisition from Azaya Therapeutics, Inc. (“Azaya”) of substantially all of the assets and the assumption of certain of liabilities, pursuant to an Asset Purchase Agreement. Pursuant to the Acquisition, Cytori has acquired the rights, title and interest in and to (i) Azaya’s ATI-0918 drug candidate, a generic bioequivalent formulation of DOXIL/CAELYX, a chemotherapy drug that is a liposomal encapsulation of doxorubicin (ATI-0918); (ii) Azaya’s ATI-1123 drug candidate, a liposomal formulation of docetaxel (ATI-1123); and (iii) certain equipment, inventory and other assets necessary to develop, manufacture, test and validate ATI-0918 and ATI-1123. Under the terms of the Purchase Agreement, at the closing of the Acquisition, the Company (i) issued 1,173,241 of shares of its common stock, par value, $0.001 per share , in Azaya’s name, (A) 879,931 of which will be delivered to Azaya promptly after the Closing, and (B) 293,310 of which will be deposited into a 15-month escrow pursuant to a standard escrow agreement; and (ii) assumed the obligation to pay approximately $2.0 million of Azaya’s existing trade payables, which payments the Company intends to make at or within thirty days after the Closing. The price per share was $1.7047, which price was equal to the volume weighted average closing price of the shares on the Nasdaq Capital Market over the ten consecutive trading days ending on the trading date immediately prior to the date of the Closing Date. In addition, as of the Closing Date, the Company assumed obligations to: (i) pay Azaya fixed commercialization milestone payments based upon achievement of certain net sales milestones for ATI-0918; (ii) make certain earn-out payments to Azaya equal to a mid-single-digit percentage of net sales of ATI-0918; and (iii) make certain earn-out payments to Azaya equal to a low single-digit percentage of net sales of any product (each a “Patented Product”), including ATI-1123, that practices a claim in the related patent assigned by Azaya to the Company (the “ATI-1123 Patent”). Cytori’s aggregate earn-out payment obligations to Azaya from global net sales of both ATI-0918 and any Patented Product will not exceed $100.0 million (the “Earn-Out Cap”). Further, the Purchase Agreement provides that if Cytori enters into certain assignments, licenses or other transfers of rights to a Patented Product or the ATI-1123 Patent, the Company will pay Azaya a percentage in the low to mid-teens of the consideration received by the Company, provided, that Cytori’s aggregate payment obligation to Azaya for any such assignment, license or other transfer of rights will not exceed $50.0 million. If the Company or its successors, sublicenses or transferees sells a competing product to ATI-0918 at any time prior to satisfaction of the Earn-Out Cap, other than because ATI-0918 fails to receive marketing authorization from the European Medicines Agency within a certain period of time or fails to generate a minimum threshold of net sales within a pre-determined amount of time, then 50% of the net sales of such competing product would be deemed to be net sales of ATI-0918 under the Purchase Agreement for purposes of calculating commercialization milestone payments and earn-out payments. Both the Company and Azaya agreed to customary representations, warranties and covenants in the Purchase Agreement. Each party also agreed to customary indemnification obligations, provided, that Azaya’s maximum liability to the Company for breaches of Azaya’s representations and warranties in the Purchase Agreement and any ancillary agreements entered into in connection therewith, is limited to $3.9 million, subject to limited exceptions. Lease Agreement On February 27, 2017, Cytori entered into a Lease Agreement (the “Lease”) with 6262 Lusk Investors LLC, a California limited liability company (“Landlord”), for approximately 29,499 square feet of office space for the Company’s corporate headquarters in San Diego, California. The initial term of the Lease is 63 months, and may be extended upon mutual agreement of the Company and the Landlord. The Lease is scheduled to commence on November 1, 2017 date, unless the premises are earlier occupied by the Company or the commencement date is delayed to allow for substantial completion of tenant improvements. Under the Lease, the Company will be obligated to pay base rent as follows (in thousands): • Year 1: $761; • Year 2: $784; • Year 3: $807; • Year 4: $832; • Year 5: $857; • Months 61-63: $74 per month ($882 annualized base rent). In addition to the base rent, the Company will also be obligated under the Lease to make certain payments for operating expenses, property taxes, insurance, insurance deductibles and other amounts. In connection with the Lease, the Company issued a letter of credit, or Letter of Credit, in favor of the Landlord in the initial principal amount of $0.1 million, which Letter of Credit will increase to $0.3 million on June 1, 2017, and to $0.5 million on the commencement date. The Letter of Credit will remain in effect for the term of the Lease. The Company has agreed to customary indemnifications of the Landlord and its affiliates arising out of the Company’s use of the rented premises, breaches of the Company’s obligations under the Lease and similar matters (except to the extent arising out of the Landlord’s gross negligence or willful misconduct).

SCHEDULE II - VALUATION AND QUA

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2016
Valuation And Qualifying Accounts [Abstract]
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	( a ) (2) Financial Statement Schedules SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS For the years ended December 31, 2016 and 2015 (in thousands) Balance at beginning of year Additions (A) Deductions (B) Other (C) Balance at end of year Allowance for doubtful accounts Year ended December 31, 2016 $ 797 $ — $ (630 ) $ — $ 167 Year ended December 31, 2015 $ 1,523 $ — $ (709 ) $ (17 ) $ 797 (A) Includes charges to costs and expenses. (B) Deductions for uncollectible accounts receivable includes payments collected and devices recovered from customers. (C) Miscellaneous activity.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Our most significant estimates and critical accounting policies involve recognizing revenue, reviewing goodwill and intangible assets for impairment, determining the assumptions used in measuring share-based compensation expense, measuring accretion expense related to our acquisition of the joint venture, and valuing allowances for doubtful accounts and inventory reserves. Actual results could differ from these estimates. Management’s estimates and assumptions are reviewed regularly, and the effects of revisions are reflected in the consolidated financial statements in the periods they are determined to be necessary.
Cash and cash equivalents	Cash and cash equivalents We consider all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents includes cash in readily available checking and savings accounts. We held no investments as of December 31, 2016 and 2015. We maintain our cash at insured financial institutions.
Restricted Cash	Restricted Cash Restricted cash consists of cash invested in a certificate of deposit used as collateral for the issuance of a letter of credit pursuant to a lease agreement entered into on April 2, 2010 (amended November 4, 2011) for leasing of property at 3020 and 3030 Callan Road, San Diego, California. The lease agreement required us to execute a letter of credit for $0.4 million naming the landlord as a beneficiary. It is required by the landlord that we maintain $0.4 million as restricted cash for the duration of the lease, which expires October 31, 2017.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company periodically assesses the collectability of accounts receivable on a specific customer basis considering factors such as evaluation of collectability, historical collection experience, the age of accounts receivable and other currently available evidence of the collectability, and records an allowance for doubtful accounts for the estimated uncollectible amount. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.
Inventories	Inventories Inventories include the cost of material, labor, and overhead related to Celution devices, consumable kits, and reagents, and are stated at the lower of cost, determined on the first-in, first-out (FIFO) method, or market. We periodically evaluate our on-hand stock and make appropriate provisions for any stock deemed excess or obsolete. Manufacturing costs resulting from lower than “normal” production levels are expensed as incurred.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation expense, which includes the amortization of capitalized leasehold improvements, is provided for on a straight-line basis over the estimated useful lives of the assets, or the life of the lease, whichever is shorter, and range from three to five years. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in operations. Maintenance and repairs are charged to operations as incurred.
Impairment	Impairment We assess certain of our long-lived assets, such as property and equipment and intangible assets other than goodwill, for potential impairment when there is a change in circumstances that indicates carrying values of assets may not be recoverable. Such long-lived assets are deemed to be impaired when the undiscounted cash flows expected to be generated by the asset (or asset group) are less than the asset’s carrying amount. Any required impairment loss would be measured as the amount by which the asset’s carrying value exceeds its fair value, and would be recorded as a reduction in the carrying value of the related asset and a charge to operating expense. We recognized no impairment losses during any of the periods presented in these financial statements.
Goodwill and Intangibles	Goodwill and Intangibles Goodwill is reviewed for impairment annually or more frequently if indicators of impairment exist. We perform our impairment test annually during the fourth quarter. The impairment evaluation is performed assuming the Company operates in a single operating segment and reporting unit. First the Company assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If, after assessing qualitative factors, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. If deemed necessary, a two-step test is used to identify the potential impairment and to measure the amount of goodwill impairment, if any. The first step is to compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is considered not impaired; otherwise, there is an indication that goodwill may be impaired and the amount of the loss, if any, is measured by performing step two. Under step two, the impairment loss, if any, is measured by comparing the implied fair value of the reporting unit goodwill with the carrying amount of goodwill. There was no indication of impairment of goodwill for all periods presented. Separable intangible assets that have finite useful lives are amortized over their respective useful lives. As part of the May 2013 acquisition of the Joint Venture (see Note 4), we acquired intangible assets which consisted primarily of contractual license rights that had previously enabled the Joint Venture to conduct development and manufacturing activities pertaining to certain aspects of Cytori’s Celution technology. The useful life of the identifiable intangible assets was estimated based on the assumed future economic benefit expected to be received from the assets. The technology was valued at $9.4 million and is being amortized on a straight-line basis over a useful life of eleven years, commensurate with the expected cash flows. The changes in the carrying amounts of finite-life intangible assets and goodwill for the years ended December 31, 2016 and 2015 are as follows (in thousands): December 31, 2016 Other intangibles, net: Beginning balance $ 9,031 Increase — Amortization (584 ) Ending balance 8,447 Goodwill, net: Beginning balance 3,922 Increase (decrease) — Ending balance 3,922 Total goodwill and other intangibles, net $ 12,369 December 31, 2015 Other intangibles, net: Beginning balance $ 9,415 Increase 13 Amortization (397 ) Ending balance 9,031 Goodwill, net: Beginning balance 3,922 Increase (decrease) — Ending balance 3,922 Total goodwill and other intangibles, net $ 12,953
Warrant Liability	Warrant Liability In connection with the October 2014 Securities Purchase Agreement, the Company issued common stock purchase warrants (the “October 2014 Warrants”) to certain institutional investors with certain exercise price reset features. Each warrant had an initial exercise price of $0.5771 per share, was exercisable six months and one day after the date of issuance and was to expire five years from the date on which it was initially exercisable. Pursuant to the second closing of the May 2015 Securities Purchase Agreement, the exercise price of these warrants was reset to $0.3263. The initial fair value of the liability associated with these warrants was $10.0 million and it decreased to $3.3 million as of December 17, 2015 when these warrants were cashless exercised by all holders. In May 2015, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell up to $25 million of units, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock, in a registered direct offering. The May 2015 Securities Purchase Agreement contemplated two closings, the first of which occurred on May 8, 2015, the second of which occurred upon satisfaction of certain conditions precedent, including, but not limited to, receipt of required stockholder approval, on August 27, 2015. Each warrant issued at the initial closing (the “May 2015 Warrants”) had an initial exercise price of $1.02 per share, was exercisable six months and one day after the date of issuance and expires five years from the date on which it is initially exercisable. Each warrant issued at the second closing (the “August 2015 Warrants”) had an initial exercise price of $0.401 per share, and was to expire five years from the date of issuance. The initial fair value of the liability associated with the May 2015 Warrants was $14.3 million and it decreased to $5.0 million as of December 17, 2015 when these warrants were cashless exercised by all holders. The initial fair value of the liability associated with the August 2015 Warrants was $1.6 million, and it decreased to $1.5 million as of December 17, 2015, when these warrants were cashless exercised by all holders. On December 17, 2015, the Company and the holders of October 2014 Warrants agreed to amend the October 2014 Warrants pursuant to an Amendment to Common Stock Purchase Warrant (the “2014 Amendment”). Also on December 17, 2015, the Company and the holders of the May 2015 Warrants and the August 2015 Warrants (collectively the “2015 Warrants”) agreed to amend the 2015 Warrants pursuant to an Amendment to Series A-1 Warrant to Purchase Common Stock and Amendment to Series A-2 Warrant to Purchase Common Stock, respectively (the “2015 Amendment” and, together with the 2014 Amendment, the “Warrant Amendments”). The Warrant Amendments provide that the holders may exercise their warrants on a “cashless exercise” basis in whole on or prior to December 31, 2015, whereby each exercising holder of the amended 2015 Warrants would receive 0.75 shares for each warrant share exercised and each exercising holder of the amended 2014 Warrants would receive 0.69 shares for each warrant share exercised. In addition, the Warrant Amendments removed certain provisions which provided that the exercise price of the Warrants would be reset in the event of certain equity issuances by the Company for a price below the exercise price of the Warrants as of the time of such issuance. All warrants were cashless exercised on or before December 31, 2015. The warrants were not traded in an active securities market and, as such, the estimated fair value as of their exercise date on December 17, 2015 was determined by using the Monte Carlo option pricing model. The 2014 and 2015 warrants were settled on or prior to December 31, 2015.
Revenue Recognition	Revenue Recognition Product Sales We recognize revenue from product sales when the following fundamental criteria are met: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred, (iii) the price to the customer is fixed or determinable and (iv) collection of the resulting accounts receivable is reasonably assured. We evaluate customers that have not developed a sufficient payment history with us or for whom a letter of credit is not in place at the time of the transaction and defer revenues until collectability is reasonably assured. For all sales, we use a binding purchase order or a signed agreement as evidence of an arrangement. If the other revenue recognition criteria are met, revenue for these product sales is recognized upon delivery to the customer as all risks and rewards of ownership have been substantively transferred to the customer at that point. For sales to customers who arrange for and manage the shipping process, we recognize revenue upon shipment from our facilities. Shipping and handling costs that are billed to our customers are classified as revenue. The customer’s obligation to pay and the payment terms are set at the time of delivery and are not dependent on the subsequent use or resale of our products. For sales where all revenue recognition criteria are not met, revenue is deferred and related inventory remains on our books. Concentration of Significant Customers & Geographical Sales For the year ended December 31, 2016, our sales were concentrated with respect to two distributors and three direct customers, which comprised 65% of our product revenue recognized. Two direct customers accounted for 57% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2016. For the year ended December 31, 2015, our sales were concentrated with respect to one distributor and four direct customers, which comprised 63% of our product revenue recognized. Two direct customers accounted for 73% of total outstanding accounts receivable (excluding receivables from BARDA) as of December 31, 2015. Product revenues, classified by geographic location, are as follows (in thousands): Years ended December 31, 2016 2015 Product Revenues % of Total Product Revenues % of Total Americas $ 936 20 % $ 982 20 % Japan 3,279 71 % 2,394 50 % EMEA 379 8 % 675 14 % Asia Pacific 62 1 % 787 16 % Total product revenues $ 4,656 100 % $ 4,838 100 % Development Revenues We earn revenue for performing tasks under research and development agreements with governmental agencies like BARDA. Revenues derived from reimbursement of direct out-of-pocket expenses for research costs associated with government contracts are recorded as government contract and other within development revenues. Government contract revenue is recorded at the gross amount of the reimbursement. The costs associated with these reimbursements are reflected as a component of research and development expense in our statements of operations. We recognized $6.7 million and $6.8 million in BARDA revenue for the years ended December 31, 2016 and 2015, respectively.
Research and Development	Research and Development Research and development expenditures, which are charged to operations in the period incurred, include costs associated with the design, development, testing and enhancement of our products, regulatory fees, the purchase of laboratory supplies, and pre-clinical and clinical studies as well as salaries and benefits for our research and development employees. Also included in research and development expenditures are costs incurred to support the government reimbursement contract, including $6.3 million and $6.3 million of qualified expenses that were incurred for the years ended December 31, 2016 and 2015, related to our government contract with BARDA.
Deferred Financing Costs and Other Debt-Related Costs	Deferred Financing Costs and Other Debt-Related Costs Deferred financing costs are capitalized, recorded as an offset to debt balances and amortized to interest expense over the term of the associated debt instrument using the effective interest method. If the maturity of the debt is accelerated because of default or early debt repayment, then the amortization would be accelerated.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. Due to our history of losses, a full valuation allowance has been recognized against our deferred tax assets. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December 31, 2016 and 2015, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months.
Share-Based Compensation	Share-Based Compensation We recognize the fair value of all share-based payment awards in our statements of operations over the requisite vesting period of each award, which approximates the period during which the employee and non-employee director is required to provide service in exchange for the award. We estimate the fair value of these options using the Black-Scholes option pricing model using assumptions for expected volatility, expected term, and risk-free interest rate. Expected volatility is based primarily on historical volatility and is computed using daily pricing observations for recent periods that correspond to the expected term of the options. The expected term is calculated based on historical data for and applied to all employee awards as a single group as we do not expect (nor does historical data suggest) substantially different exercise or post-vesting termination behavior amongst our employee population. The risk-free interest rate is the interest rate for treasury instruments with maturities that approximate the expected term.
Segment Information	Segment Information For the years ended December 31, 2016 and 2015, all of our financial results relate to cell therapy, therefore we report our results in one operating segment.
Loss Per Share	Loss Per Share Basic per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted per share data is computed by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding as calculated using the treasury stock method. Potential common shares were related entirely to outstanding but unexercised options and warrants for all periods presented. We have excluded all potentially dilutive securities, including unvested performance-based restricted stock, from the calculation of diluted loss per share attributable to common stockholders for the years ended December 31, 2016 and 2015, as their inclusion would be antidilutive. Potentially dilutive securities excluded from the calculations of diluted loss per share were 4.2 million as of December 31, 2016, which includes 3.6 million outstanding warrants and 0.6 million options and restricted stock awards. Potentially dilutive securities excluded from the calculations of diluted loss per share were 12.3 million as of December 31, 2015.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-12, Revenue from Contracts with Customers In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In July 2015, FASB issued ASU 2015-11, Simplifying the Measurement of Inventory In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of certain cash receipts and cash payments In November 2016, the FASB issued Accounting Standards Update No. 2016-18, Restricted Cash In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Clarifying the Definition of a Business In February 2017, the FASB recently issued ASU 2017-04, Simplifying the Test for Goodwill Impairment

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Intangible Assets and Goodwill	The changes in the carrying amounts of finite-life intangible assets and goodwill for the years ended December 31, 2016 and 2015 are as follows (in thousands): December 31, 2016 Other intangibles, net: Beginning balance $ 9,031 Increase — Amortization (584 ) Ending balance 8,447 Goodwill, net: Beginning balance 3,922 Increase (decrease) — Ending balance 3,922 Total goodwill and other intangibles, net $ 12,369 December 31, 2015 Other intangibles, net: Beginning balance $ 9,415 Increase 13 Amortization (397 ) Ending balance 9,031 Goodwill, net: Beginning balance 3,922 Increase (decrease) — Ending balance 3,922 Total goodwill and other intangibles, net $ 12,953
Product Revenues, Classified by Geographic Location	Product revenues, classified by geographic location, are as follows (in thousands): Years ended December 31, 2016 2015 Product Revenues % of Total Product Revenues % of Total Americas $ 936 20 % $ 982 20 % Japan 3,279 71 % 2,394 50 % EMEA 379 8 % 675 14 % Asia Pacific 62 1 % 787 16 % Total product revenues $ 4,656 100 % $ 4,838 100 %

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2016
Financial Instruments Financial Liabilities Balance Sheet Groupings [Abstract]
Summary of change in Level 3 warrant liability	The following table summarizes the final valuation pertaining to the warrants that were previously included in our Level 3 warrant liabilities (in thousands): Warrant liability December 31, 2015 Balance as of December 31, 2014 $ 9,793 Additions to warrant liability 15,979 Exercised warrants (18,104 ) Change in fair value (7,668 ) Balance as of December 31, 2015 $ —
Fair Value and Carrying Value of Long-term Debt	At December 31, 2016 and 2015, the aggregate fair value and the carrying value of the Company’s long-term debt were as follows (in thousands): December 31, 2016 December 31, 2015 Fair Value Carrying Value Fair Value Carrying Value Debt $ 17,611 $ 17,637 $ 16,844 $ 16,681

Composition of Certain Financ25

Composition of Certain Financial Statement Captions (Tables)	12 Months Ended
	Dec. 31, 2016
Composition Of Certain Financial Statement Captions [Abstract]
Inventories, net	Inventories, net As of December 31, 2016 and 2015, inventories, net, were comprised of the following (in thousands): December 31, 2016 2015 Raw materials $ 885 $ 1,009 Work in process 1,021 816 Finished goods 1,819 2,473 $ 3,725 $ 4,298
Other Current Assets	Other Current Assets As of December 31, 2016 and 2015, other current assets were comprised of the following (in thousands): December 31, 2016 2015 Prepaid supplies, current $ 734 $ 995 Prepaid insurance 83 300 Other receivables 53 260 $ 870 $ 1,555
Property and Equipment, net	Property and Equipment, net As of December 31, 2016 and 2015, property and equipment, net, were comprised of the following (in thousands): December 31, 2016 2015 Manufacturing and development equipment $ 4,256 $ 5,464 Office and computer equipment 1,953 1,939 Leasehold improvements 3,399 3,391 9,608 10,794 Less accumulated depreciation (8,451 ) (9,163 ) $ 1,157 $ 1,631
Other Assets	Other Assets As of December 31, 2016 and 2015, other assets were comprised of the following (in thousands): December 31, 2016 2015 Prepaid supplies, long-term $ 1,838 $ 996 Deposits 498 525 $ 2,336 $ 1,521
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses As of December 31, 2016 and 2015, accounts payable and accrued expenses were comprised of the following (in thousands): December 31, 2016 2015 Accrued expenses $ 1,752 $ 2,022 Accounts payable 1,332 1,009 Accrued payroll and bonus 989 1,058 Accrued legal fees 614 372 Accrued vacation 502 573 Accrued R&D studies 347 1,117 Deferred rent 215 221 Accrued accounting fees 121 315 $ 5,872 $ 6,687

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Minimum Purchase Obligation	We are party to an agreement with Roche Diagnostics Corporation, our sole supplier of reagents, which requires us to make certain product purchase minimums. Pursuant to the agreement, as of December 31, 2016, we have a minimum purchase obligation as follows: Years Ending December 31, Obligation 2017 $ 1,074 2018 1,074 2019 1,473 2020 1,473 2021 1,473 Total $ 6,567

Long-term Obligations (Tables)

Long-term Obligations (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Term Loan Outstanding	Additional details relating to the outstanding Term Loan as of December 31, 2016 and 2015 are presented in the following table (in thousands): Year ended December 31, 2016 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment* Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 136 48 Months $ 17,700 Year ended December 31, 2015 Origination Date Original Loan Amount Interest Rate** Current Monthly Payment*** Original Term Remaining Principal (Face Value) May 2015 $ 17,700 8.95 % $ 136 48 Months $ 17,700 * **
Future Minimum Debt and Lease Payments	As of December 31, 2016, the future contractual principal and final fee payments on all of our debt and capital lease obligations are as follows (as thousands): Years Ending December 31, 2017 $ 7,080 2018 7,080 2019 4,629 Total $ 18,789
Face Value to Book Value Reconciliation	Reconciliation of Face Value to Book Value as of December 31, 2016 Total debt and lease obligations, including final payment fee (Face Value) $ 18,789 Less: Debt discount (1,152 ) Total obligation $ 17,637

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Reconciliation of Total Income Tax Provision	A reconciliation of the total income tax provision tax rate to the statutory federal income tax rate of 34% for the years ended December 31, 2016 and 2015 is as follows: 2016 2015 Income tax expense (benefit) at federal statutory rate (34.00 )% (34.00 )% Income tax expense (benefit) at state statutory rate (3.41 )% (4.40 )% Mark to market permanent adjustment 0.00 % (13.91 )% Change in valuation allowance 16.75 % (7.45 )% Change in state rate (0.06 )% (0.09 )% Permanent interest adjustments 0.16 % 6.25 % Stock compensation 12.67 % 20.43 % Transfer pricing 0.00 % 18.49 % Research credit (1.44 )% (2.37 )% Foreign rate differential 0.79 % 0.69 % NOLs expiring and adjustments to NOL 6.00 % 13.92 % Other, net 2.54 % 2.44 % 0.00 % 0.00 %
Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to significant portions of our deferred tax assets and deferred tax liabilities as of December 31, 2016 and 2015 are as follows (in thousands): 2016 2015 Deferred tax assets: Allowances and reserves $ 573 $ 673 Accrued expenses 701 951 Deferred revenue and gain-on-sale 33 39 Stock based compensation 1,947 4,547 Net operating loss carryforwards 125,182 119,000 Income tax credit carryforwards 7,764 7,437 Property and equipment, principally due to differences in depreciation 675 683 Other, net 15 16 136,890 133,346 Valuation allowance (134,873 ) (131,187 ) Total deferred tax assets, net of allowance 2,017 2,159 Deferred tax liabilities: Intangibles assets (2,017 ) (2,159 ) Total deferred tax liability (2,017 ) (2,159 ) Net deferred tax assets (liability) $ — $ —
Unrecognized Tax Benefits Activity	Following is a tabular reconciliation of the unrecognized tax benefits activity during the years ended December 31, 2016 and 2015 (in thousands): 2016 2015 Unrecognized Tax Benefits – Beginning $ 1,987 $ 1,852 Gross increases – tax positions in prior period 1 — Gross decreases – tax positions in prior period (13 ) — Gross increase – current-period tax positions 87 135 Unrecognized Tax Benefits – Ending $ 2,062 $ 1,987

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Option Activity	A summary of activity for the year ended December 31, 2016 is as follows: Options Weighted Average Exercise Price Balance as of January 1, 2016 573,727 $ 44.85 Granted 347,407 $ 2.73 Expired (23,979 ) $ 104.11 Cancelled/forfeited (261,043 ) $ 32.07 Balance as of December 31, 2016 636,112 $ 24.39
Stock Options Vested and Expected to Vest	Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Balance as of December 31, 2016 636,112 $ 24.39 7.38 $ — Vested and expected to vest at December 31, 2016 598,135 $ 25.72 7.27 $ — Exercisable at December 31, 2016 286,358 $ 47.76 5.54 $ —
Weighted-average Assumptions	The fair value of each option awarded during the year ended December 31, 2016 and 2015 was estimated on the date of grant using the Black-Scholes-Merton option valuation model based on the following weighted-average assumptions: Years ended December 31, 2016 2015 Expected term 6.0 years 6.0 years Risk-free interest rate 1.75 % 1.58 % Volatility 77.56 % 75.07 % Dividends — — Resulting weighted average grant date fair value $ 1.84 $ 4.50
Restricted Stock Awards Activity	A summary of activity for the year ended December 31, 2016 is as follows: Restricted Stock Awards Weighted Average Grant Date Fair Value Balance as of January 1, 2016 31,196 $ 12.15 Vested/Released (11,568 ) $ 15.18 Cancelled/forfeited (19,113 ) $ 10.03 Balance as of December 31, 2016 515 $ 64.52
Compensation Cost Recognized for Stock Options and Restricted Stock Awards	The following summarizes the total compensation cost recognized for the stock options and restricted stock awards in the accompanying financial statements (in thousands): Years ended December 31, 2016 2015 Total compensation cost for share-based payment arrangements recognized in the statement of operations (net of tax of $0) $ 1,080 $ 2,041

Quarterly Information (unaudi30

Quarterly Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Unaudited Quarterly Financial Information	The following unaudited quarterly financial information includes, in management’s opinion, all the normal and recurring adjustments necessary to fairly state the results of operations and related information for the periods presented (in thousands): For the three months ended March 31, 2016 June 30, 2016 September 30, 2016 December 31, 2016 Product revenues $ 1,333 $ 1,126 $ 731 $ 1,466 Gross profit 766 541 113 521 Development revenues 1,585 1,699 1,879 1,561 Operating expenses (7,448 ) (8,464 ) (6,789 ) (5,670 ) Other expense, net (242 ) (181 ) (587 ) (1,330 ) Net income (loss) $ (5,339 ) $ (6,405 ) $ (5,384 ) $ (4,918 ) Beneficial conversion feature for convertible preferred stock — — — — Net income (loss) allocable to common stock holders (5,339 ) (6,405 ) (5,384 ) (4,918 ) Basic and diluted net loss per share $ (0.41 ) $ (0.43 ) $ (0.26 ) $ (0.24 ) For the three months ended March 31, 2015 June 30, 2015 September 30, 2015 December 31, 2015 Product revenues $ 902 $ 1,614 $ 766 $ 1,556 Gross profit 305 318 264 765 Development revenues 1,444 1,847 1,710 1,820 Operating expenses (22,745 ) 3,626 16 (4,656 ) Other expense, net (961 ) (1,342 ) (470 ) (685 ) Net income (loss) $ (21,957 ) $ 4,449 $ 1,520 $ (2,756 ) Beneficial conversion feature for convertible preferred stock (661 ) — — — Net income (loss) allocable to common stock holders (22,618 ) 4,449 1,520 (2,756 ) Basic and diluted net loss per share $ (3.19 ) $ 0.45 $ 0.15 $ (0.25 )

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Schedule of Base Rent Payments	Under the Lease, the Company will be obligated to pay base rent as follows (in thousands): • Year 1: $761; • Year 2: $784; • Year 3: $807; • Year 4: $832; • Year 5: $857; • Months 61-63: $74 per month ($882 annualized base rent).

Organization and Operations - A

Organization and Operations - Additional Information (Details)	Dec. 22, 2016USD ($)	Jun. 16, 2016USD ($)shares	May 10, 2016shares	Dec. 31, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)shares	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2016USD ($)Subsidiary$ / sharesshares	Dec. 31, 2015USD ($)shares	Jun. 15, 2016$ / sharesshares	May 11, 2016shares	Dec. 31, 2014USD ($)shares
Basis Of Presentation And New Accounting Standards [Line Items]
Number of wholly-owned subsidiaries | Subsidiary												5
Reverse stock split of common stock			15
Common stock, shares outstanding (in shares) | shares			200,000,000	21,707,890				13,003,893				21,707,890	13,003,893		13,300,000
Number of shares callable by warrants (in shares) | shares			16,000,000											1	1,100,000
Common stock, shares authorized (in shares) | shares			290,000,000	75,000,000				75,000,000				75,000,000	75,000,000		75,000,000
Net loss				$ 4,918,000	$ 5,384,000	$ 6,405,000	$ 5,339,000	$ 2,756,000	$ (1,520,000)	$ (4,449,000)	$ 21,957,000	$ 22,046,000	$ 18,744,000
Accumulated deficit				379,063,000				357,017,000				379,063,000	357,017,000
Net cash used in operating activities												19,533,000	20,468,000
Cash and cash equivalents				12,560,000				$ 14,338,000				12,560,000	14,338,000			$ 14,622,000
Payments of principal amount in monthly installments												600,000
Minimum cash/cash equivalents covenant				$ 5,000,000								5,000,000
Common stock issued (in shares) | shares		6,704,852
Each unit consist of number of warrant | shares		3,352,306
Warrant exercise price (in dollars per share) | $ / shares														$ 3.06
Proceeds from issuance warrants		$ 17,100,000
Common stock issued, value												$ 19,478,000	$ 10,701,000
Common Stock [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Common stock, shares outstanding (in shares) | shares				21,707,890				13,003,893				21,707,890	13,003,893			6,623,225
Number of shares callable by warrants (in shares) | shares				1								1
Common stock issued (in shares) | shares		6,704,852										8,673,253	2,560,711
Each unit consist of number of warrant | shares												0.5
Warrant exercise price (in dollars per share) | $ / shares				$ 3.06								$ 3.06
Common stock issued, value												$ 9,000	$ 2,000
Period exercisable from the date of issuance												30 months
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Common stock issued, value	$ 20,000,000
Period exercisable from the date of issuance	30 months
Minimum [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Unrestricted cash and cash equivalents				$ 5,000,000								$ 5,000,000
2014 Equity Incentive Plan [Member]
Basis Of Presentation And New Accounting Standards [Line Items]
Number of shares callable by warrants (in shares) | shares			6,500,000												400,000

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Additional Information (Details)	1 Months Ended		12 Months Ended
	May 31, 2015USD ($)Closing$ / sharesshares	May 31, 2013	Dec. 31, 2016USD ($)DistributorCustomerSegment$ / sharesshares	Dec. 31, 2015USD ($)DistributorCustomerSegmentshares	Jun. 15, 2016$ / sharesshares	May 11, 2016shares	May 10, 2016shares	Dec. 17, 2015USD ($)shares	Aug. 31, 2015USD ($)
Summary Of Significant Accounting Policies [Line Items]
Cash equivalents investments with original maturities			$ 0	$ 0
Impairment loss			0	0
Impairment of goodwill			0	0
Acquired technology intangible assets			9,400,000
Useful life (in years)		11 years
Amortization expense			584,000	397,000
2,017			1,200,000
2,018			1,200,000
Thereafter			6,000,000
Accumulated amortization on intangible assets			1,200,000	600,000
Exercise price per shares (in dollars per share) | $ / shares					$ 3.06
Common stock issued, value			$ 19,478,000	$ 10,701,000
Number of shares callable by warrants (in shares) | shares					1	1,100,000	16,000,000
Period of services provided subsequent to date of sale			1 year
Concentration risk percentage			100.00%	100.00%
Total development revenues			$ 6,724,000	$ 6,821,000
Qualifying expenditures related to research			6,300,000	6,300,000
Interest or penalties related to income tax matters			$ 0	$ 0
Number of operating segment | Segment			1	1
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares			4,200,000	12,300,000
Options and Restricted Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares			600,000
BARDA Contract [Member]
Summary Of Significant Accounting Policies [Line Items]
Total development revenues			$ 6,700,000	$ 6,800,000
Customer Concentration Risk [Member] | Revenue Recognized [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of distributor | Distributor			2	1
Number of customers | Customer			3	4
Concentration risk percentage			65.00%	63.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer			2	2
Concentration risk percentage			57.00%	73.00%
Securities Purchase Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Common stock issued, value	$ 25,000,000
Number of closings | Closing	2
Warrant [Member]
Summary Of Significant Accounting Policies [Line Items]
Warrant liability			$ 10,000,000
Dilutive securities excluded from the calculations of diluted loss per share (in shares) | shares			3,600,000
Warrant [Member] | Securities Purchase Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of shares callable by warrants (in shares) | shares	1
Common Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Exercise price per shares (in dollars per share) | $ / shares			$ 3.06
Period exercisable from the date of issuance			30 months
Common stock issued, value			$ 9,000	$ 2,000
Number of shares callable by warrants (in shares) | shares			1
Common Stock [Member] | 2015 Amendment [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of shares callable by each warrant (in shares) | shares								0.75
Common Stock [Member] | 2014 Amendment [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of shares callable by each warrant (in shares) | shares								0.69
Common Stock [Member] | Securities Purchase Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of shares callable by warrants (in shares) | shares	1
Number of shares callable by each warrant (in shares) | shares	1
October 2014 warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Exercise price per shares (in dollars per share) | $ / shares			$ 0.5771
Period exercisable from the date of issuance			6 months 1 day
Expiration term of warrant			5 years
Warrant liability								$ 3,300,000
October 2015 warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Exercise price per shares (in dollars per share) | $ / shares	$ 0.3263
May 2015 Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Exercise price per shares (in dollars per share) | $ / shares	$ 1.02
Period exercisable from the date of issuance			6 months 1 day
Expiration term of warrant			5 years
Warrant liability	$ 14,300,000							5,000,000
August 2015 Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Exercise price per shares (in dollars per share) | $ / shares	$ 0.401
Expiration term of warrant			5 years
Warrant liability								$ 1,500,000	$ 1,600,000
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets			3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Useful lives of the assets			5 years
Letter of Credit [Member]
Summary Of Significant Accounting Policies [Line Items]
Letter of credit amount required by lease agreement			$ 400,000
Restricted cash required to maintained under Lease agreement			$ 400,000
Lease expiration date			Oct. 31, 2017

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Other intangibles, net:
Other intangibles, net, Beginning balance	$ 9,031	$ 9,415
Other intangibles, net, Increase		13
Other intangibles, net, Amortization	(584)	(397)
Other intangibles, net, Ending balance	8,447	9,031
Goodwill, net, Beginning balance	3,922	3,922
Goodwill, net Ending balance	3,922	3,922
Total goodwill and other intangibles, net	$ 12,369	$ 12,953

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Product Revenues, Classified by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Concentration Risk [Line Items]
Revenues	$ 1,466	$ 731	$ 1,126	$ 1,333	$ 1,556	$ 766	$ 1,614	$ 902	$ 4,656	$ 4,838
Concentration risk percentage									100.00%	100.00%
Americas [Member]
Concentration Risk [Line Items]
Revenues									$ 936	$ 982
Concentration risk percentage									20.00%	20.00%
Japan [Member]
Concentration Risk [Line Items]
Revenues									$ 3,279	$ 2,394
Concentration risk percentage									71.00%	50.00%
EMEA [Member]
Concentration Risk [Line Items]
Revenues									$ 379	$ 675
Concentration risk percentage									8.00%	14.00%
Asia Pacific [Member]
Concentration Risk [Line Items]
Revenues									$ 62	$ 787
Concentration risk percentage									1.00%	16.00%

Agreement with Lorem Vascular (

Agreement with Lorem Vascular (Details) - Lorem Vascular [Member] $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2013USD ($)Installment$ / sharesshares
Partnership Agreement [Line Items]
Percentage of gross profits required to pay as per agreement	30.00%
Exclusive License [Member]
Partnership Agreement [Line Items]
Total commitment	$ 500
Equity Purchases [Member]
Partnership Agreement [Line Items]
Total commitment	$ 24
Shares of unregistered stock purchased (in shares) | shares	8
Equity purchase price (in dollars per share) | $ / shares	$ 3
Number of installments in equity purchases | Installment	2
Product Purchase Commitment [Member]
Partnership Agreement [Line Items]
First purchase commitment	$ 1.8

Transactions with Olympus Cor37

Transactions with Olympus Corporation (Details) - USD ($)	Apr. 30, 2015	Dec. 31, 2016
Termination of Olympus' Interest in the Joint Venture [Abstract]
Total purchase price	$ 6,000,000
Purchase price payment agreement term		2 years
Amendment One to Joint Venture Termination Agreement [Member]
Termination of Olympus' Interest in the Joint Venture [Abstract]
Purchase price payment termination agreement total	4,200,000
Purchase price principal amount payable on January 31, 2016	500,000
Purchase price principal amount payable on April 30, 2016	500,000
Purchase price principal amount and accrued interest payable on May 8, 2016	$ 800,000
Purchase price payable obligations outstanding balance.		$ 0

Fair Value - Summary of Change

Fair Value - Summary of Change in Level 3 Warrant Liability (Details) - Fair Value, Measurements, Recurring [Member] - Level 3 [Member] - Warrants [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Change in Level 3 liability [Roll Forward]
Balance as of December 31, 2014	$ 9,793
Additions to warrant liability	15,979
Exercised warrants	(18,104)
Change in fair value	$ (7,668)

Fair Value - Fair Value and Car

Fair Value - Fair Value and Carrying Value of Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	$ 17,611	$ 16,844
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt	$ 17,637	$ 16,681

Disclosure - Fair Value - Addit

Disclosure - Fair Value - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt discount	$ 1.2	$ 2.1

Composition of Certain Financ41

Composition of Certain Financial Statement Captions - Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventories, net [Abstract]
Raw materials	$ 885	$ 1,009
Work in process	1,021	816
Finished goods	1,819	2,473
Inventories, net	$ 3,725	$ 4,298

Composition of Certain Financ42

Composition of Certain Financial Statement Captions - Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Current Assets [Abstract]
Prepaid supplies, current	$ 734	$ 995
Prepaid insurance	83	300
Other receivables	53	260
Total other current assets	$ 870	$ 1,555

Composition of Certain Financ43

Composition of Certain Financial Statement Captions - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property and Equipment, net [Abstract]
Manufacturing and development equipment	$ 4,256	$ 5,464
Office and computer equipment	1,953	1,939
Leasehold improvements	3,399	3,391
Property and equipment, gross	9,608	10,794
Less accumulated depreciation	(8,451)	(9,163)
Property and equipment, net	$ 1,157	$ 1,631

Composition of Certain Financ44

Composition of Certain Financial Statement Captions - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Composition Of Certain Financial Statement Captions [Abstract]
Depreciation expense	$ 0.7	$ 0.7

Composition of Certain Financ45

Composition of Certain Financial Statement Captions - Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Assets [Abstract]
Prepaid supplies, long-term	$ 1,838	$ 996
Deposits	498	525
Total other assets	$ 2,336	$ 1,521

Composition of Certain Financ46

Composition of Certain Financial Statement Captions - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounts Payable and Accrued Expenses [Abstract]
Accrued expenses	$ 1,752	$ 2,022
Accounts payable	1,332	1,009
Accrued payroll and bonus	989	1,058
Accrued legal fees	614	372
Accrued vacation	502	573
Accrued R&D studies	347	1,117
Deferred rent	215	221
Accrued accounting fees	121	315
Accounts payable and accrued expenses, Total	$ 5,872	$ 6,687

Commitments and Contingencies47

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation	$ 18,789
Contractual obligation, due in next twelve months	7,080
Pre-clinical Research Study Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation	3,300
Contractual obligation, due in next twelve months	3,200
Operating Lease Obligations [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Contractual obligation	1,800
Contractual obligation, due in next twelve months	1,800
Rent expense	$ 2,500	$ 2,500

Commitments and Contingencies -

Commitments and Contingencies - Minimum Purchase Obligation (Details) $ in Thousands	Dec. 31, 2016USD ($)
Purchase Obligation Fiscal Year Maturity [Abstract]
2,017	$ 1,074
2,018	1,074
2,019	1,473
2,020	1,473
2,021	1,473
Total	$ 6,567

Long-term Obligations (Details)

Long-term Obligations (Details) - USD ($)		May 29, 2015	Dec. 31, 2016	Dec. 31, 2015		Jun. 15, 2016	May 11, 2016	May 10, 2016
Debt Instrument [Line Items]
Number of shares callable by warrants (in shares)						1	1,100,000	16,000,000
Warrant exercise price (in dollars per share)						$ 3.06
Repayment of long term debt			$ 0	$ 25,032,000
Unamortized debt discount			1,152,000
Loss on debt extinguishment			0	(260,000)
Minimum liquidity covenant			5,000,000
Future contractual principal and final fee payments on all debt and capital lease obligations [Abstract]
2,017			7,080,000
2,018			7,080,000
2,019			4,629,000
Contractual principal and final fee payments, Total			18,789,000
Reconciliation of Face Value to Book Value [Abstract]
Total debt and lease obligations, including final payment fee (Face Value)			18,789,000
Less: Debt discount			(1,152,000)
Total obligation			17,637,000
Interest expense			2,592,000	3,379,000
Non-cash amortization			$ 1,000,000	$ 1,000,000
LIBOR [Member] | Interest Rate Floor [Member]
Debt Instrument [Line Items]
Basis variable rate		1.00%
Term Loan [Member]
Debt Instrument [Line Items]
Origination Date			May 29, 2015	May 29, 2015
Original Loan Amount		$ 17,700,000	$ 17,700,000	$ 17,700,000
Basis variable rate		7.95%
Maturity date			Jun. 1, 2019
Fees amount associated with loan		$ 1,100,000
Number of shares callable by warrants (in shares)		94,441
Warrant exercise price (in dollars per share)		$ 10.35
Date from which warrants are exercisable			Nov. 30, 2015
Warrant expiration date			May 29, 2025
Repayment of long term debt		$ 25,400,000
Remaining Principal (Face Value)		23,400,000	$ 17,700,000	17,700,000
Accrued but unpaid interest		200,000
Final payment fee		1,800,000
Principal amount of previous loan retired		3,100,000
Unamortized debt discount		$ 800,000
Loss on debt extinguishment				$ 300,000
Effective interest rate		14.95%
Minimum liquidity covenant		$ 5,000,000
Debt instrument, covenant compliance			we were in compliance with the debt covenants
Additional details relating term loan that is outstanding [Abstract]
Origination Date			May 29, 2015	May 29, 2015
Original Loan Amount		17,700,000	$ 17,700,000	$ 17,700,000
Interest Rate	[1]		8.95%	8.95%
Current Monthly Payment	[2]		$ 136,000	$ 136,000	[1]
Original Term			48 months	48 months
Remaining Principal (Face Value)		23,400,000	$ 17,700,000	$ 17,700,000
Reconciliation of Face Value to Book Value [Abstract]
Less: Debt discount		(800,000)
Term Loan [Member] | Final Payment [Member]
Debt Instrument [Line Items]
Fees amount associated with loan		$ 800,000
Minimum [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Interest rate		8.95%
[1]	3 month LIBOR rate with a floor of 1% plus 7.95%
[2]	Monthly payment as of December 2016, which reflects interest only

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Provision or benefit for income taxes	$ 0	$ 0
Current federal or state income tax provision		0
Deferred federal or state income tax provision		0
Income Tax Contingency [Abstract]
Valuation allowance	134,873,000	131,187,000
Increase in valuation allowance	$ 3,700,000
Net operating loss carryforwards, Expire date	Begin to expire in 2019 and 2017
State tax credit carryforwards	$ 4,400,000
Cumulative change in ownership	50.00%
Period of net operating loss and R&D tax credit carry forwards to offset future taxable income	3 years
Excess tax benefits	$ 1,300,000
Liability for uncertain tax positions	$ 0	$ 0
Period for material changes of liability for uncertain tax benefits	12 months
Federal [Member]
Income Tax Contingency [Abstract]
Tax loss carryforwards	$ 344,200,000
Federal tax carry forward	$ 4,900,000
Federal tax credit carryforward, Expiration date	Begin to expire in 2018
State [Member]
Income Tax Contingency [Abstract]
Tax loss carryforwards	$ 158,100,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Total Income Tax Provision (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of the total income tax provision tax rate [Abstract]
Income tax expense (benefit) at federal statutory rate	(34.00%)	(34.00%)
Income tax expense (benefit) at state statutory rate	(3.41%)	(4.40%)
Mark to market permanent adjustment	0.00%	(13.91%)
Change in valuation allowance	16.75%	(7.45%)
Change in state rate	(0.06%)	(0.09%)
Permanent interest adjustments	0.16%	6.25%
Stock compensation	12.67%	20.43%
Transfer pricing	0.00%	18.49%
Research credit	(1.44%)	(2.37%)
Foreign rate differential	0.79%	0.69%
NOLs expiring and adjustments to NOL	6.00%	13.92%
Other, net	2.54%	2.44%
Total income tax provision	0.00%	0.00%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets [Abstract]
Allowances and reserves	$ 573	$ 673
Accrued expenses	701	951
Deferred revenue and gain-on-sale	33	39
Stock based compensation	1,947	4,547
Net operating loss carryforwards	125,182	119,000
Income tax credit carryforwards	7,764	7,437
Property and equipment, principally due to differences in depreciation	675	683
Other, net	15	16
Deferred tax assets (Total)	136,890	133,346
Valuation allowance	(134,873)	(131,187)
Total deferred tax assets, net of allowance	2,017	2,159
Deferred tax liabilities [Abstract]
Intangibles assets	(2,017)	(2,159)
Total deferred tax liability	(2,017)	(2,159)
Net deferred tax assets (liability)	$ 0	$ 0

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule of reconciliation of unrecognized tax benefits activity [Roll Forward]
Unrecognized Tax Benefits – Beginning	$ 1,987	$ 1,852
Gross increases – tax positions in prior period	1	0
Gross decreases – tax positions in prior period	(13)	0
Gross increase – current-period tax positions	87	135
Unrecognized Tax Benefits – Ending	$ 2,062	$ 1,987

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Discretionary or matching contributions	$ 0	$ 0

Stockholders' Equity (Details)

Stockholders' Equity (Details)	Dec. 31, 2016$ / sharesshares	Dec. 22, 2016USD ($)$ / sharesshares	Jun. 16, 2016USD ($)shares	Aug. 27, 2015USD ($)shares	May 08, 2015USD ($)	May 31, 2015USD ($)Closingshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)	Jun. 15, 2016$ / sharesshares	May 11, 2016shares	May 10, 2016shares	Dec. 17, 2015shares	Mar. 31, 2015USD ($)
Preferred Stock [Abstract]
Preferred stock, shares authorized (in shares)	5,000,000						5,000,000	5,000,000
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.001						$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	13,500						13,500	13,500
Convertible preferred stock							3.60%	3.60%	3.60%
Series A convertible preferred stock, shares outstanding	0						0	0
Common Stock [Abstract]
Common stock issued, value | $							$ 19,478,000	$ 10,701,000
Number of shares callable by warrants (in shares)										1	1,100,000	16,000,000
Common stock issued (in shares)			6,704,852
Common stock, shares authorized (in shares)	75,000,000						75,000,000	75,000,000			75,000,000	290,000,000
Proceeds from sale of common stock | $							$ 21,467,000	$ 29,054,000
Each unit consist of number of warrant			3,352,306
Warrant exercise price (in dollars per share) | $ / shares										$ 3.06
Common Stock [Member]
Common Stock [Abstract]
Common stock issued, value | $							$ 9,000	$ 2,000
Number of shares callable by warrants (in shares)	1						1
Common stock issued (in shares)			6,704,852				8,673,253	2,560,711
Common Stock Subscription Price | $ / shares							$ 2.55
Each unit consist of number of common stock	1						1
Each unit consist of number of warrant							0.5
Warrant exercise price (in dollars per share) | $ / shares	$ 3.06						$ 3.06
Period exercisable from the date of issuance							30 months
Gross proceeds from private placement of stock | $			$ 15,300,000
Redemption price of warrant prior to expiration | $ / shares	$ 0.01						$ 0.01
Common stock price per share for warrant redemption | $ / shares							$ 7.65
Number of consecutive trading days for warrant redemption							10 days
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued, value | $		$ 20,000,000
Period exercisable from the date of issuance		30 months
Common Stock [Member] | Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued, value | $		$ 200,000
Common stock issued (in shares)	0
Common Stock [Member] | Maximum [Member] | Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Floor price of per share | $ / shares		$ 0.50
Common Stock [Member] | Minimum [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Beneficial ownership percentage of common stock outstanding		9.99%
Common Stock [Member] | 2015 Amendment [Member]
Common Stock [Abstract]
Number of shares callable by each warrant (in shares)													0.75
Common Stock [Member] | 2014 Amendment [Member]
Common Stock [Abstract]
Number of shares callable by each warrant (in shares)													0.69
ATM [Member]
Common Stock [Abstract]
Common stock issued (in shares)							1,840,982	5,800,000
Proceeds from sale of common stock | $							$ 4,400,000	$ 7,200,000
Securities Purchase Agreement [Member]
Common Stock [Abstract]
Common stock issued, value | $						$ 25,000,000
Number of closings | Closing						2
Securities Purchase Agreement [Member] | Initial Closing [Member]
Common Stock [Abstract]
Proceeds from private placement of stock | $					$ 17,400,000
Securities Purchase Agreement [Member] | Second Closing [Member]
Common Stock [Abstract]
Proceeds from private placement of stock | $				$ 2,100,000
Common stock issued (in shares)				500,000
Common stock, shares authorized (in shares)				1,000,000
Securities Purchase Agreement [Member] | Common Stock [Member]
Common Stock [Abstract]
Number of shares callable by warrants (in shares)						1
Number of shares callable by each warrant (in shares)						1
Securities Purchase Agreement [Member] | Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)		127,419
Trading Volume of Common Shares		0
Common stock issued (in shares)		382,258
Securities Purchase Agreement [Member] | Warrant [Member]
Common Stock [Abstract]
Number of shares callable by warrants (in shares)						1
Single Regular Purchase [Member] | Common Stock [Member] | Maximum [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued (in shares)		100,000
Single Regular Purchase [Member] | Common Stock [Member] | Minimum [Member] | Lincoln Park Capital Fund, LLC [Member]
Common Stock [Abstract]
Common stock issued, value | $		$ 1,000,000
Dividend Paid [Member]
Preferred Stock [Abstract]
Dividends payable | $														$ 700,000
Dividend Declared [Member]
Preferred Stock [Abstract]
Dividends payable | $									$ 70,000

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)	May 31, 2016	Dec. 29, 2015	Aug. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Securities remaining and available for future issuances (in shares)				49,708,768
Stock Option Activity [Abstract]
Stock option vesting period				4 years
Stock option contractual term				10 years
Stock option vesting provisions				12/48 of a granted award will vest after one year of service, while an additional 1/48 of the award will vest at the end of each month thereafter for 36 months, or 1/48 of the award will vest at the end of each month over a four-year period.
Weighted Average Remaining Contractual Terms [Abstract]
Stock options exercised				$ 0	$ 0
Dividend yield assumed				0
Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards				$ 1,000,000
Weighted average period for recognition of cost				1 year 6 months 29 days
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares to be issued (in shares)	333,333		301,800	265,000
Securities remaining and available for future issuances (in shares)				525,965
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares to be issued (in shares)		66,666

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Options [Roll Forward]
Balance as of January 1, 2016 (in shares) | shares	573,727
Granted (in shares) | shares	347,407
Expired (in shares) | shares	(23,979)
Cancelled/forfeited (in shares) | shares	(261,043)
Balance as of December 31, 2016 (in shares) | shares	636,112
Weighted Average Exercise Price [Roll Forward]
Balance as of January 1, 2016 (in dollars per share) | $ / shares	$ 44.85
Granted (in dollars per share) | $ / shares	2.73
Expired (in dollars per share) | $ / shares	104.11
Cancelled/forfeited (in dollars per share) | $ / shares	32.07
Balance as of December 31, 2016 (in dollars per share) | $ / shares	$ 24.39

Stock-based Compensation - St58

Stock-based Compensation - Stock Options Vested and Expected to Vest (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options [Roll Forward]
Balance as of December 31, 2016 (in shares)	636,112	573,727
Vested and expected to vest at December 31, 2016 (in shares)	598,135
Exercisable at December 31, 2016 (in shares)	286,358
Weighted Average Exercise Price [Roll Forward]
Balance as of December 31, 2016 (in dollars per share)	$ 24.39
Vested and expected to vest at December 31, 2016 (in dollars per share)	25.72
Exercisable at December 31, 2016 (in dollars per share)	$ 47.76
Weighted Average Remaining Contractual Term [Roll Forward]
Balance as of December 31, 2016	7 years 4 months 17 days
Vested and expected to vest at December 31, 2016	7 years 3 months 7 days
Exercisable at December 31, 2016	5 years 6 months 15 days

Stock-based Compensation - Weig

Stock-based Compensation - Weighted-average Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Black-Scholes-Merton option valuation model based on weighted-average assumptions [Abstract]
Expected term	6 years	6 years
Risk-free interest rate	1.75%	1.58%
Volatility	77.56%	75.07%
Resulting weighted average grant date fair value (in dollars per share)	$ 1.84	$ 4.50

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Awards Activity (Details) - Restricted Stock Awards [Member]	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Restricted Stock Awards, Performance-Based Restricted Stock Awards [Roll Forward]
Outstanding, Beginning Balance (in shares) | shares	31,196
Vested/Released (in shares) | shares	(11,568)
Cancelled/forfeited (in shares) | shares	(19,113)
Outstanding, Ending Balance (in shares) | shares	515
Weighted Average Grant Date Fair Value [Roll Forward]
Balance as of January 1, 2016 (in dollars per share) | $ / shares	$ 12.15
Vested/Released (in dollars per share) | $ / shares	15.18
Cancelled/forfeited (in dollars per share) | $ / shares	10.03
Balance as of December 31, 2016 (in dollars per share) | $ / shares	$ 64.52

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Cost Recognized for Stock Options and Restricted Stock Awards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Compensation cost recognized for the stock options and restricted stock awards [Abstract]
Total compensation cost for share-based payment arrangements recognized in the statement of operations (net of tax of $0)	$ 1,080	$ 2,041

Stock-based Compensation - Co62

Stock-based Compensation - Compensation Cost Recognized for Stock Options and Restricted Stock Awards (Parenthetical) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Total compensation cost for share-based payment arrangements recognized in the statement of operations, tax	$ 0	$ 0

Quarterly Information (unaudi63

Quarterly Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Product revenues	$ 1,466	$ 731	$ 1,126	$ 1,333	$ 1,556	$ 766	$ 1,614	$ 902	$ 4,656	$ 4,838
Gross profit	521	113	541	766	765	264	318	305	1,941	1,652
Development revenues	1,561	1,879	1,699	1,585	1,820	1,710	1,847	1,444
Operating expenses	(5,670)	(6,789)	(8,464)	(7,448)	(4,656)	16	3,626	(22,745)
Other expense, net	(1,330)	(587)	(181)	(242)	(685)	(470)	(1,342)	(961)	(2,340)	(3,458)
Net loss	(4,918)	(5,384)	(6,405)	(5,339)	(2,756)	1,520	4,449	(21,957)	(22,046)	(18,744)
Beneficial conversion feature for convertible preferred stock	0	0	0	0	0	0	0	(661)	0	(661)
Net loss allocable to common stockholders	$ (4,918)	$ (5,384)	$ (6,405)	$ (5,339)	$ (2,756)	$ 1,520	$ 4,449	$ (22,618)	$ (22,046)	$ (19,405)
Basic and diluted net loss per share	$ (0.24)	$ (0.26)	$ (0.43)	$ (0.41)	$ (0.25)	$ 0.15	$ 0.45	$ (3.19)	$ (1.28)	$ (2.07)

Subsequent Events (Details)

Subsequent Events (Details)	Feb. 15, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / shares	Nov. 01, 2017USD ($)	Jun. 01, 2017USD ($)	Feb. 27, 2017USD ($)ft²	Dec. 31, 2015$ / shares
Subsequent Event [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.001				$ 0.001
Initial lease term		63 months
Lease commencement date		Nov. 1, 2017
Letter of Credit [Member]
Subsequent Event [Line Items]
Letter of credit amount required by lease agreement		$ 400,000
Letter of Credit [Member] | Scenario Forecast [Member]
Subsequent Event [Line Items]
Letter of credit amount required by lease agreement			$ 500,000	$ 300,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Area of office space leased | ft²					29,499
Subsequent Event [Member] | Letter of Credit [Member]
Subsequent Event [Line Items]
Letter of credit amount required by lease agreement					$ 100,000
Subsequent Event [Member] | Asset Purchase Agreement [Member] | Azaya Therapeutics, Inc. [Member]
Subsequent Event [Line Items]
Common stock, shares issued | shares	1,173,241
Common stock, par value (in dollars per share) | $ / shares	$ 0.001
Common stock, shares issued after closing date | shares	879,931
Common stock deposited in escrow | shares	293,310
Obligation to pay on existing trade payables assumed	$ 2,000,000
Shares issued, price per share | $ / shares	$ 1.7047
Number of consecutive trading days	10 days
Maximum earn-out payment obligations	$ 100,000,000
Aggregate payment obligation threshold limit	$ 50,000,000
Percentage of net sales deemed for purposes of calculating payments	50.00%
Maximum liability of customary indemnification obligations	$ 3,900,000

Subsequent Events - Schedule of

Subsequent Events - Schedule of Base Rent Payments (Details) - Subsequent Event [Member] $ / mo in Thousands, $ in Thousands	Feb. 27, 2017USD ($)$ / mo
Subsequent Event [Line Items]
Base rent, Year 1	$ 761
Base rent, Year 2	784
Base rent, Year 3	807
Base rent, Year 4	832
Base rent, Year 5	857
Base rent, Months 61-63	$ 882
Base rent, Months 61-63 | $ / mo	74

SCHEDULE II - VALUATION AND Q66

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at beginning of year		$ 797	$ 1,523
Additions	[1]	0	0
Deductions	[2]	(630)	(709)
Other	[3]		(17)
Balance at end of year		$ 167	$ 797
[1]	Includes charges to costs and expenses
[2]	Deductions for uncollectible accounts receivable includes payments collected and devices recovered from customers
[3]	Miscellaneous activity